

Nivolumab and Ipilimumab versus Ipilimumab in Untreated

New England Journal of Medicine

372, 2006-2017

DOI: [10.1056/nejmoa1414428](https://doi.org/10.1056/nejmoa1414428)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. Translational Lung Cancer Research, 2007, 6, 186-195.	1.3	13
2	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 220-229.	1.3	10
3	Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. Journal of Immunology, 2008, 181, 7660-7669.	0.4	181
4	Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma. Experimental Hematology and Oncology, 2015, 5, 9.	2.0	1
5	Targeting immune checkpoints in melanoma: an update. Melanoma Management, 2015, 2, 339-352.	0.1	2
7	Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma. Annals of Surgical Oncology, 2015, 22, 356-361.	0.7	26
8	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in Cancer, 2015, 7s2, BIC.S29325.	3.6	51
9	Novel melanoma therapy. Experimental Hematology and Oncology, 2015, 5, 23.	2.0	8
10	Integrating first-line treatment options into clinical practice. Melanoma Research, 2015, 25, 461-469.	0.6	25
11	Radiation with immunotherapy: an emerging combination for cancer treatment. Journal of Radiation Oncology, 2015, 4, 331-338.	0.7	5
15	Nivolumab plus ipilimumab in the treatment of advanced melanoma. Journal of Hematology and Oncology, 2015, 8, 123.	6.9	42
17	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
18	Painless Thyroiditis with Thyrotoxicosis or Hypothyroidism May Develop in Patients Receiving Programmed Death 1 Receptor Immunotherapy. Clinical Thyroidology, 2015, 27, 185-186.	0.0	1
19	Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. The Cochrane Library, 2015, 2015, CD010341.	1.5	32
21	What's new in melanoma? Combination!. Journal of Translational Medicine, 2015, 13, 213.	1.8	38
22	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	1.8	56
23	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Research, 2015, 25, 555-558.	0.6	35
24	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.1	4

#	ARTICLE	IF	CITATIONS
25	Recent advances in antibody-based therapies for Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 171-178.	1.2	4
26	The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 305-309.	0.1	1
27	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. <i>Pharmacotherapy</i> , 2015, 35, 963-976.	1.2	183
28	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 482-488.	1.1	31
29	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17
30	Myeloid Cells as Targets for Therapy in Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 343-350.	1.0	32
31	Nivolumab in the treatment of malignant melanoma: review of the literature. <i>OncoTargets and Therapy</i> , 2015, 8, 2045.	1.0	21
32	Treating melanoma in adolescents and young adults: challenges and solutions. <i>Clinical Oncology in Adolescents and Young Adults</i> , 2015, , 75.	0.8	2
33	Evaluación positiva de medicamentos: marzo/abril/mayo 2015. <i>Sanidad Militar</i> , 2015, 71, 186-195.	0.0	0
34	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	1.7	61
35	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. <i>Oncotarget</i> , 2015, 6, 37117-37134.	0.8	80
36	Targeting C-Type Lectin Receptors for Cancer Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 408.	2.2	80
37	Lymphoma Immunotherapy: Current Status. <i>Frontiers in Immunology</i> , 2015, 6, 448.	2.2	36
38	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
39	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73
40	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 152.	1.3	26
41	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. <i>Frontiers in Oncology</i> , 2015, 5, 202.	1.3	201
42	Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. , 2015, 3, P126.		2

#	ARTICLE	IF	CITATIONS
43	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <i>Viruses</i> , 2015, 7, 5889-5901.	1.5	19
44	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
45	TIGIT predominantly regulates the immune response via regulatory T cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4053-4062.	3.9	470
47	Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. <i>BioMed Research International</i> , 2015, 2015, 1-22.	0.9	60
48	Immunotherapy in Tumors. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 809-15.	0.6	31
49	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. <i>Cancers</i> , 2015, 7, 1959-1982.	1.7	32
51	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
52	Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.	0.9	11
53	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. <i>Cancer Immunology Research</i> , 2015, 3, 1292-1298.	1.6	38
54	Talimogene laherparepvec in the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1517-1530.	1.4	8
55	The use of combinations of monoclonal antibodies in clinical oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 859-867.	3.4	79
56	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
57	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. <i>Current Anesthesiology Reports</i> , 2015, 5, 257-267.	0.9	0
58	A ã€˜fitã™ microbiota to potentiate cancer immunotherapy. <i>Genome Medicine</i> , 2015, 7, 131.	3.6	10
59	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	0.8	19
60	Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 1812-1819.	1.5	9
61	Tã€cell receptor gene therapy ã€˜ready to go viral?. <i>Molecular Oncology</i> , 2015, 9, 2019-2042.	2.1	21
62	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 129.	6.9	223

#	ARTICLE	IF	CITATIONS
63	Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 969-975.	1.1	38
65	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. , 2015, 3, 58.		26
66	Combination cancer immunotherapy and new immunomodulatory targets. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 561-584.	21.5	1,058
68	The evolving role of CETP inhibition: beyond HDL cholesterol. <i>Lancet, The</i> , 2015, 386, 412-414.	6.3	11
69	Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1444-1455.	3.7	18
70	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^Δ /IL2R ^Δ null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.4	137
71	Pembrolizumab for the treatment of melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 515-527.	1.3	2
72	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	4.0	158
73	T-cell exhaustion in the tumor microenvironment. <i>Cell Death and Disease</i> , 2015, 6, e1792-e1792.	2.7	743
74	Combined immunotherapyâ€”a new standard in metastatic melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 439-440.	12.5	8
75	Inhibition of BRAF and MEK in BRAF-mutant melanoma. <i>Lancet, The</i> , 2015, 386, 410-412.	6.3	8
76	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
77	Trametinib in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 749-760.	1.1	8
78	Engineered materials for cancer immunotherapy. <i>Nano Today</i> , 2015, 10, 511-531.	6.2	96
79	Nivolumab in the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 945-956.	0.5	0
80	Radiotherapy and immune checkpoint blockade: potential interactions and future directions. <i>Trends in Molecular Medicine</i> , 2015, 21, 463-465.	3.5	28
81	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 1270-1271.	13.9	785
82	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17

#	ARTICLE	IF	CITATIONS
83	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
84	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
85	Predictors of clinical response to immunotherapy with or without radiotherapy. <i>Journal of Radiation Oncology</i> , 2015, 4, 339-345.	0.7	17
86	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. <i>Dermatology and Therapy</i> , 2015, 5, 151-169.	1.4	19
87	Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 997-1004.	1.1	58
90	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	6.0	639
91	Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. <i>Molecular Oncology</i> , 2015, 9, 1918-1935.	2.1	104
92	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
93	Nivolumab: A Review in Advanced Melanoma. <i>Drugs</i> , 2015, 75, 1413-1424.	4.9	44
94	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 981-993.	1.1	59
95	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma? An exclamation sign with a question mark. <i>Oncolmmunology</i> , 2015, 4, e1058037.	2.1	27
96	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. <i>Future Oncology</i> , 2015, 11, 2299-2306.	1.1	20
97	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
98	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
99	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 914-924.	3.4	41
100	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , 2015, 21, 1128-1138.	15.2	268
101	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. <i>Lancet Oncology</i> , The, 2015, 16, e522-e526.	5.1	20
102	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12

#	ARTICLE	IF	CITATIONS
103	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101
104	Update on Mucin-1 immunotherapy in cancer: a clinical perspective. Expert Opinion on Biological Therapy, 2015, 15, 1773-1787.	1.4	36
105	Endocrine resistance in breast cancer – An overview and update. Molecular and Cellular Endocrinology, 2015, 418, 220-234.	1.6	280
106	Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discovery, 2015, 5, 915-919.	7.7	495
107	Pembrolizumab. , 2015, 3, 36.		171
108	Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66.	0.1	151
109	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	6.0	2,275
110	Neopeptides of Cancers: Looking Back, Looking Ahead. Cancer Immunology Research, 2015, 3, 969-977.	1.6	59
111	Breast cancer and immunology: biomarker and therapeutic developments. Expert Review of Anticancer Therapy, 2015, 15, 1215-1222.	1.1	9
112	Cell Death and Cancer Therapy: Don't Forget to Kill the Cancer Cell!. Clinical Cancer Research, 2015, 21, 5015-5020.	3.2	23
113	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1 derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 2015, 15, 1389-1403.	1.1	102
114	Nivolumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1789-1797.	1.4	27
115	Could microbial therapy boost cancer immunotherapy?. Science, 2015, 350, 1031-1032.	6.0	36
116	<i>In situ</i> vaccination: Cancer immunotherapy both personalized and off-the-shelf. Molecular Oncology, 2015, 9, 1966-1981.	2.1	139
117	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology and Oncology, 2015, 8, 104.	6.9	139
118	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2015, 7, 1213-1227.	1.0	77
119	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. Seminars in Oncology, 2015, 42, S12-S19.	0.8	24
120	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Current Treatment Options in Oncology, 2015, 16, 57.	1.3	30

#	ARTICLE	IF	CITATIONS
121	Challenges in the use of immunotherapy in metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216681.	0.2	1
122	The Paradox of Anti-cancer Agents and Recurring Emergence of Drug Resistance. <i>Journal of Biomedical Sciences</i> , 2016, 05, .	0.3	0
123	The steady progress of targeted therapies, promising advances for lung cancer. <i>Ecancermedicalsecience</i> , 2016, 10, 638.	0.6	6
124	Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. , 2016, 20, 15-149.		2
126	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
127	Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. <i>BioScience Trends</i> , 2016, 10, 85-91.	1.1	35
128	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2149.	1.8	2
129	Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer. <i>Current Cancer Therapy Reviews</i> , 2016, 12, 23-36.	0.2	0
130	Current trends in the treatment of malignant melanoma. <i>Neoplasma</i> , 2016, 63, 333-341.	0.7	11
131	Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 81-86.	0.4	12
132	New targeted treatments for non-small-cell lung cancer – role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117.	3.0	23
133	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	0.6	84
134	Management of Melanoma Therapy-Associated Toxicities. , 2016, , 299-319.		1
135	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e505-e514.	1.8	10
136	Biomarkers for Immunotherapy: Current Developments and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e493-e503.	1.8	85
137	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e558-e564.	1.8	8
138	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
139	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 173.	0.8	28

#	ARTICLE	IF	CITATIONS
140	Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 479-486.	0.6	21
142	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	0.8	100
143	Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. <i>Sarcoma</i> , 2016, 2016, 1-6.	0.7	20
144	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). <i>Medical Journal of Australia</i> , 2016, 205, 418-424.	0.8	29
145	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2
147	Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Journal of Cancer</i> , 2016, 7, 1599-1604.	1.2	8
148	Inflammation and Cancer. , 2016, , 406-415.		10
149	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
150	A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. <i>Frontiers in Immunology</i> , 2016, 7, 326.	2.2	22
151	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
152	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
153	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
154	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39
155	Updates in Therapy for Advanced Melanoma. <i>Cancers</i> , 2016, 8, 17.	1.7	37
156	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
157	Immune Mechanisms in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 944.	1.8	48
158	Combined Immune Therapy for the Treatment of Visceral Leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004415.	1.3	33
159	Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. <i>PLoS ONE</i> , 2016, 11, e0161779.	1.1	172

#	ARTICLE	IF	CITATIONS
160	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3153-3161.	2.0	29
161	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25.	0.2	29
162	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget, 2016, 7, 74350-74361.	0.8	35
163	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	1.0	7
164	Radiation therapy and the abscopal effect: a concept comes of age. Annals of Translational Medicine, 2016, 4, 118-118.	0.7	61
166	Immune Checkpoint Therapy in Melanoma. Cancer Journal (Sudbury, Mass), 2016, 22, 73-80.	1.0	10
167	Treatment of melanoma brain metastases. Current Opinion in Oncology, 2016, 28, 159-165.	1.1	11
168	Side-effects of checkpoint inhibitor-based combination therapy. Current Opinion in Oncology, 2016, 28, 306-313.	1.1	41
169	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	1.2	26
170	Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research, 2016, 26, 284-289.	0.6	21
171	Combination immunotherapy for cancer. Journal of Experimental Medicine, 2016, 213, 1115-1115.	4.2	4
172	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy, 2016, 8, 821-837.	1.0	139
173	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (Kras ^{G12D/+} ; Trp53 ^{R172H/+} ; Pdx1 ^{Cre}), Its Variants, and Their Application in Immunology and Oncology Drug Discovery. Current Protocols in Pharmacology, 2016, 73, 14.39.1-14.39.20.	4.0	141
174	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. Current Opinion in Oncology, 2016, 28, 185-191.	1.1	17
175	Future directions in the treatment of osteosarcoma. Current Opinion in Pediatrics, 2016, 28, 26-33.	1.0	228
176	Managing Adverse Events With Immune Checkpoint Agents. Cancer Journal (Sudbury, Mass), 2016, 22, 121-129.	1.0	42
177	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer, 2016, 98, 51-58.	0.9	110
178	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Current Opinion in Oncology, 2016, 28, 254-263.	1.1	213

#	ARTICLE	IF	CITATIONS
179	Irradiation and immunotherapy: From concept to the clinic. <i>Cancer</i> , 2016, 122, 1659-1671.	2.0	73
180	Update on immune therapy in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 799-808.	0.5	0
181	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	1.1	39
182	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	3.4	667
183	New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. <i>Clinical Cancer Research</i> , 2016, 22, 4283-4290.	3.2	29
184	Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer. , 2016, , 129-162.		1
185	Immune checkpoint inhibitors side effects and management. <i>Immunotherapy</i> , 2016, 8, 799-807.	1.0	62
186	Recent advances in immunoœoncology and its application to urological cancers. <i>BJU International</i> , 2016, 118, 506-514.	1.3	12
187	Updates in the management of brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1043-1065.	0.6	209
188	Ocular and orbital side-effects of checkpoint inhibitors: a review article. <i>Current Opinion in Oncology</i> , 2016, 28, 288-294.	1.1	117
189	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93
190	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	2.3	76
191	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	2.0	55
192	Synthesis of a Sulfonimidamide-Based Analog of Tasisulam and Its Biological Evaluation in the Melanoma Cell Lines SKMel23 and A375. <i>Skin Pharmacology and Physiology</i> , 2016, 29, 281-290.	1.1	29
193	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , 2016, 22, S1-S137.	3.2	29
194	What does PD-L1 positive or negative mean?. <i>Journal of Experimental Medicine</i> , 2016, 213, 2835-2840.	4.2	263
195	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91
196	Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). <i>Oncology Reports</i> , 2016, 36, 1779-1786.	1.2	14

#	ARTICLE	IF	CITATIONS
197	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54
198	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. Oncology Nursing Forum, 2016, 43, 219-226.	0.5	18
199	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
200	Update in Hematology and Oncology: Evidence Published in 2015. Annals of Internal Medicine, 2016, 164, W32.	2.0	0
201	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy, 2016, 8, 1437-1446.	1.0	25
202	Immune checkpoint inhibitors renal side effects and management. Immunotherapy, 2016, 8, 1417-1425.	1.0	13
203	The cutting edge of metastatic melanoma therapy. Melanoma Management, 2016, 3, 217-229.	0.1	1
205	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
206	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research, 2016, 26, 469-480.	0.6	30
207	Role of immune cells in pancreatic cancer from bench to clinical application. Medicine (United States), 2016, 95, e5541.	0.4	118
208	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. Genes and Diseases, 2016, 3, 252-256.	1.5	17
211	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	1.8	27
212	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. Critical Reviews in Oncology/Hematology, 2016, 101, 213-220.	2.0	39
213	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology, 2016, 5, e1165377.	2.1	42
214	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	6.9	271
215	Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Management, 2016, 3, 149-159.	0.1	1
216	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. Melanoma Management, 2016, 3, 137-147.	0.1	1
217	Repeat courses of SRS in patients initially treated with SRS alone for brain-metastatic melanoma. Melanoma Management, 2016, 3, 97-104.	0.1	5

#	ARTICLE	IF	CITATIONS
218	Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 857-867.	2.0	53
219	Targeting neoantigens for cancer immunotherapy: Table 1.. <i>International Immunology</i> , 2016, 28, 365-370.	1.8	42
220	Intralesional treatment for advanced melanoma: what's on the horizon?. <i>Melanoma Management</i> , 2016, 3, 113-123.	0.1	0
221	What Is New in Melanoma Genetics and Treatment?. <i>Dermatology</i> , 2016, 232, 259-264.	0.9	25
222	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	1.8	54
223	Malignant melanomaâ€™The cradle of anti-neoplastic immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 25-54.	2.0	33
224	Patient-Physician Communication in the 21st Century. <i>Trends in Immunology</i> , 2016, 37, 347-349.	2.9	1
225	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 753-763.	2.0	32
226	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	6.6	418
227	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	1.1	107
228	Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. <i>Melanoma Research</i> , 2016, 26, 329-337.	0.6	11
229	Targeting PD-L1 for non-small-cell lung cancer. <i>Immunotherapy</i> , 2016, 8, 747-758.	1.0	12
230	Endocrinological side-effects of immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 278-287.	1.1	115
231	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 575-577.	0.2	6
232	CIS is a potent checkpoint in NK cellâ€™mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
233	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1323-1332.	3.7	28
234	Immune checkpoint inhibitors: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 555-564.	2.4	46
235	Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. <i>Targeted Oncology</i> , 2016, 11, 553-556.	1.7	32

#	ARTICLE	IF	CITATIONS
236	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
237	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
238	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. <i>Neuro-Oncology</i> , 2016, 18, 601-602.	0.6	2
239	The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. <i>Gynecologic Oncology</i> , 2016, 142, 184-189.	0.6	18
240	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
241	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. <i>Current Opinion in Immunology</i> , 2016, 40, vii-xiii.	2.4	20
242	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
243	Embracing rejection: Immunologic trends in brain metastasis. <i>Oncolmmunology</i> , 2016, 5, e1172153.	2.1	33
244	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
245	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8
246	Future Medicine 2: Cancer Vaccines. , 2016, , 249-284.		0
247	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
248	Novel Therapies in Castration-Resistant Prostate Cancer. , 2016, , 259-269.		0
249	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
250	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
251	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 665-674.	1.0	39
252	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 577-584.	1.1	12
253	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. <i>American Journal of Pathology</i> , 2016, 186, 1537-1546.	1.9	31

#	ARTICLE	IF	CITATIONS
254	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
256	Adapting Cancer Immunotherapy Models for the Real World. Trends in Immunology, 2016, 37, 354-363.	2.9	77
257	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	1.8	412
258	Current Challenges in Cancer Treatment. Clinical Therapeutics, 2016, 38, 1551-1566.	1.1	549
259	TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy, 2016, 8, 511-519.	1.0	14
260	The integration of radiation therapy and immunotherapy in melanoma management. Journal of Radiation Oncology, 2016, 5, 131-142.	0.7	2
261	Zebrafish Melanoma. Advances in Experimental Medicine and Biology, 2016, 916, 439-450.	0.8	10
262	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology, 2016, 5, e1151595.	2.1	57
263	Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncology, The, 2016, 17, 1471-1472.	5.1	20
264	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncology, 2016, 12, 2683-2688.	1.1	17
265	Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. ACS Nano, 2016, 10, 8956-8963.	7.3	275
266	Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. Journal of Clinical Oncology, 2016, 34, 3605-3608.	0.8	72
267	Combination therapeutics in complex diseases. Journal of Cellular and Molecular Medicine, 2016, 20, 2231-2240.	1.6	76
268	Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer, 2016, 2, 286-294.	3.8	270
269	Inmunoterapia del melanoma. Piel, 2016, 31, 649-656.	0.0	0
270	Immunotherapy of Melanoma. Oncology Research and Treatment, 2016, 39, 369-376.	0.8	14
271	Gemcitabine reduces MDSCs, tregs and TGFÎ²-1 while restoring the teff/treg ratio in patients with pancreatic cancer. Journal of Translational Medicine, 2016, 14, 282.	1.8	152
272	Anti-PD1â€œInduced Pneumonitis: Capturing the Hidden Enemy. Clinical Cancer Research, 2016, 22, 5956-5958.	3.2	12

#	ARTICLE	IF	CITATIONS
273	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. <i>European Journal of Cancer</i> , 2016, 68, 70-72.	1.3	0
274	Cardiovascular Toxic Effects of Targeted Cancer Therapies. <i>New England Journal of Medicine</i> , 2016, 375, 1457-1467.	13.9	470
275	Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 685-697.	0.4	6
276	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
277	The Systemic Management of Advanced Melanoma in 2016. <i>Oncology Research and Treatment</i> , 2016, 39, 635-642.	0.8	15
278	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	2.0	89
279	Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 1701-1716.	2.9	56
280	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.	0.9	108
281	Design of Pluronic-Based Formulation for Enhanced Redaporfin-Photodynamic Therapy against Pigmented Melanoma. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 22039-22055.	4.0	80
282	Oncolytic viruses-immunotherapeutics on the rise. <i>Journal of Molecular Medicine</i> , 2016, 94, 979-991.	1.7	43
283	PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. <i>Immunotherapy</i> , 2016, 8, 1081-1089.	1.0	32
284	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016, 63, 1490-1493.	2.9	226
285	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. <i>Cancer Research</i> , 2016, 76, 5288-5301.	0.4	82
286	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
287	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
288	Patient-derived tumor xenograft models for melanoma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 895-906.	2.5	20
289	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. <i>Cancer Medicine</i> , 2016, 5, 1481-1491.	1.3	86
290	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56

#	ARTICLE	IF	CITATIONS
291	Therapeutic implications of melanoma heterogeneity. <i>Experimental Dermatology</i> , 2016, 25, 497-500.	1.4	28
292	PD-1 Pathway Inhibitors: Immunotherapy Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
293	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	1.7	28
294	Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112.	0.6	8
295	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , 2016, 3, 231-243.	0.1	4
296	Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1552-1560.	0.5	50
297	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	2
298	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
299	CML Blast Crisis: Implications and Management. <i>Hematologic Malignancies</i> , 2016, , 147-160.	0.2	1
300	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. <i>Methods in Molecular Biology</i> , 2016, 1458, 159-177.	0.4	7
301	Cancer-Associated Tertiary Lymphoid Structures, from Basic Knowledge Toward Therapeutic Target in Clinic. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 99-125.	0.1	0
302	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 243-254.	1.0	5
303	A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 578-588.	0.4	190
304	Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 679-687.	1.5	8
305	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1255-1261.	1.5	12
306	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. <i>Annals of Oncology</i> , 2016, 27, 1658-1659.	0.6	3
307	Sequencing of New and Old Therapies for Metastatic Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 52.	1.3	7
308	Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 525-527.	0.6	6

#	ARTICLE	IF	CITATIONS
309	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
310	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
311	Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?. <i>Nature Reviews Rheumatology</i> , 2016, 12, 593-604.	3.5	81
312	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	3.4	600
313	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 538-547.	0.8	41
314	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 164-174.	2.0	134
316	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16029.	7.1	53
317	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5183-5188.	3.2	171
318	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1558-1568.	5.1	827
319	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	2.0	18
320	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. <i>Oral Oncology</i> , 2016, 61, 166-176.	0.8	11
321	Complete response to nivolumab monotherapy in a treatment-naïve, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1395-1400.	2.0	18
322	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	0.8	438
323	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144
324	Releasing the brakes to fight cancer. <i>EMBO Reports</i> , 2016, 17, 1257-1260.	2.0	4
325	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754.	1.6	131
326	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 685-695.	0.4	15
327	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 811-826.	1.1	26

#	ARTICLE	IF	CITATIONS
328	Management of side effects of immune checkpoint blockade by anti-CTLA4 and anti-PD1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.4	63
329	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA4- und PD1-Antikörper beim metastasierten Melanom. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-683.	0.4	47
330	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology, 2016, 5, e1238557.	2.1	113
331	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
332	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	5.8	412
333	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
334	Nivolumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 1247-1261.	1.1	20
335	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	2.3	106
336	Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. Journal of Hematology and Oncology, 2016, 9, 96.	6.9	21
338	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends in Molecular Medicine, 2016, 22, 1000-1011.	3.5	60
339	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	4.8	44
340	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. Oncology and Therapy, 2016, 4, 239-256.	1.0	8
341	Management of CML-blast crisis. Best Practice and Research in Clinical Haematology, 2016, 29, 295-307.	0.7	60
342	Drug Combinations as the New Standard for Melanoma Treatment. Current Treatment Options in Oncology, 2016, 17, 61.	1.3	16
343	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science Immunology, 2016, 1, aaf6925.	5.6	142
344	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
345	Approaches to modernize the combination drug development paradigm. Genome Medicine, 2016, 8, 115.	3.6	64
346	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. New England Journal of Medicine, 2016, 375, 1749-1755.	13.9	1,668

#	ARTICLE	IF	CITATIONS
347	Eph Receptor Tyrosine Kinases in Tumor Immunity. <i>Cancer Research</i> , 2016, 76, 6452-6457.	0.4	55
348	Successful Treatment of a Patient with Glioblastoma and a Germline <i>POLE</i> Mutation: Where Next?. <i>Cancer Discovery</i> , 2016, 6, 1210-1211.	7.7	14
349	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 319-326.	0.3	3
350	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. <i>Journal of Hematology and Oncology</i> , 2016, 9, 116.	6.9	201
351	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
354	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. <i>RMD Open</i> , 2016, 2, e000321.	1.8	37
355	Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. <i>Medicine (United States)</i> , 2016, 95, e3997.	0.4	12
356	Advances in treatment of metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2016, 26, 439-446.	0.9	9
357	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. <i>International Immunopharmacology</i> , 2016, 38, 81-89.	1.7	44
358	Interferon- β Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 650-657.	1.6	22
359	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	2.6	524
360	Immunotherapy in Breast Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 335-345.	0.8	14
361	Talimogene laherparepvec in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 781-788.	0.5	0
362	Merkel Cell Carcinoma Therapeutic Update. <i>Current Treatment Options in Oncology</i> , 2016, 17, 36.	1.3	88
363	Neutrophils in cancer: neutral no more. <i>Nature Reviews Cancer</i> , 2016, 16, 431-446.	12.8	1,296
364	Radicality of initial surgery for primary malignant melanoma of the vagina. <i>Melanoma Research</i> , 2016, 26, 173-180.	0.6	4
365	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208
366	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2016, 28, e127-e138.	0.6	35

#	ARTICLE	IF	CITATIONS
367	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. <i>Radiotherapy and Oncology</i> , 2016, 120, 1-12.	0.3	44
368	Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 329-333.	0.6	0
369	The development of immunotherapy in older adults: New treatments, new toxicities?. <i>Journal of Geriatric Oncology</i> , 2016, 7, 325-333.	0.5	93
370	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155.	2.9	50
372	Use of big data in drug development for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 245-253.	0.4	28
373	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
374	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
375	Prevalence of Autoimmune Disease Among Patients With Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1507.	3.4	121
376	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	5.1	1,091
377	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	5.1	293
378	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. <i>Oral Oncology</i> , 2016, 58, 49-51.	0.8	0
379	Current and future immunotherapeutic approaches in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2014-2024.	0.6	17
380	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1607-1611.	2.8	105
381	Predicting analysis times in randomized clinical trials with cancer immunotherapy. <i>BMC Medical Research Methodology</i> , 2016, 16, 12.	1.4	17
382	The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2016, 12, 339-383.	2.5	115
383	Immune Checkpoint Inhibitors in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 47.	1.8	49
384	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
385	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0

#	ARTICLE	IF	CITATIONS
386	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 951-959.	2.0	62
387	Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998.	3.2	48
388	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
389	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95
390	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
391	The role of microbiota in cancer therapy. <i>Current Opinion in Immunology</i> , 2016, 39, 75-81.	2.4	74
392	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256
393	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	1.3	1,687
394	Immunotherapy for advanced melanoma: future directions. <i>Immunotherapy</i> , 2016, 8, 199-209.	1.0	19
395	Doubling the blockade for melanoma immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1106127.	2.1	9
396	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	1.1	8
397	Metastatic colonization by circulating tumour cells. <i>Nature</i> , 2016, 529, 298-306.	13.7	1,498
398	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , 2016, 16, 121-126.	12.8	353
399	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	0.6	52
400	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2016, 91, 288-296.	1.4	17
401	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
402	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 446-459.	7.7	198
403	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 413-425.	1.1	115

#	ARTICLE	IF	CITATIONS
404	Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 397-406.	1.4	56
405	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treatment Reviews, 2016, 43, 113-123.	3.4	9
406	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology, 2016, 48, 177-187.	0.3	210
407	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	1.5	46
408	Single versus combination immunotherapy drug treatment in melanoma. Expert Opinion on Biological Therapy, 2016, 16, 433-441.	1.4	16
409	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. OncoImmunology, 2016, 5, 1136045.	2.1	22
410	CTLA-4 and PD-1 Pathways. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 98-106.	0.6	1,644
411	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. International Immunology, 2016, 28, 383-391.	1.8	223
412	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	0.8	692
413	2015 and human cancer: back to overall survival. Future Oncology, 2016, 12, 1751-1754.	1.1	0
414	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-37.	0.4	4
415	Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36.	0.4	16
416	The role of tumor microenvironment in melanoma therapy resistance. Melanoma Management, 2016, 3, 23-32.	0.1	18
417	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	3.3	23
418	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2016, 100, 88-98.	2.0	316
419	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.1	12
420	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunology Research, 2016, 4, 345-353.	1.6	214
421	A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor "dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. Cancer Immunology, Immunotherapy, 2016, 65, 383-392.	2.0	28

#	ARTICLE	IF	CITATIONS
422	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <i>Nature Medicine</i> , 2016, 22, 433-438.	15.2	721
423	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1092-1101.	1.4	37
424	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
425	Therapeutic vaccines for prostate cancer: recent advances and future directions. <i>Expert Review of Vaccines</i> , 2016, 15, 907-914.	2.0	5
426	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	3.4	354
427	The immune mechanisms of abscopal effect in radiation therapy. <i>Current Problems in Cancer</i> , 2016, 40, 10-24.	1.0	131
428	The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1174-1177.	0.6	53
429	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. <i>Immunity</i> , 2016, 44, 343-354.	6.6	767
430	Nivolumab in Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 492-494.	13.9	48
431	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
432	Merkel Cell Carcinoma: Current Issues Regarding Diagnosis, Management, and Emerging Treatment Strategies. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 49-62.	3.3	26
433	The impact of sequencing on diagnosis and treatment of malignant melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 423-433.	1.5	4
434	The management of immune-related adverse events associated with immune checkpoint blockade. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 89-97.	0.6	15
435	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. <i>Cancer Cell</i> , 2016, 29, 285-296.	7.7	349
436	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
437	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	0.7	34
438	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€“PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	0.5	48
439	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909

#	ARTICLE	IF	CITATIONS
440	Immune checkpoint pathways: perspectives on myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 995-1001.	0.6	4
441	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
442	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
443	Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1330-1338.	0.8	259
444	Molecular pathology in real time. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 129-140.	2.7	26
445	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077
446	Nivolumab-induced organizing pneumonia in a melanoma patient. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 270-272.	0.6	45
447	A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 549-557.	1.4	22
449	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 183-193.	1.0	112
450	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
451	OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. <i>Oral Oncology</i> , 2016, 52, 1-10.	0.8	56
452	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
453	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
454	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
455	The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99.	2.0	87
456	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 189-200.	2.8	34
457	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
458	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. <i>Trends in Immunology</i> , 2016, 37, 141-153.	2.9	24

#	ARTICLE	IF	CITATIONS
459	Rationale for anti-OX40 cancer immunotherapy. <i>European Journal of Cancer</i> , 2016, 52, 50-66.	1.3	264
460	Metastatic melanoma treatment: Combining old and new therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 242-253.	2.0	64
461	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 5-12.	1.1	13
462	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	12.5	753
463	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	0.6	86
464	Immunotherapy for cancer in the central nervous system: Current and future directions. <i>Oncolimmunology</i> , 2016, 5, e1082027.	2.1	72
465	Cancer Neoantigens and Applications for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 807-812.	3.2	188
466	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 886-894.	3.2	705
467	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 58-71.	3.3	49
468	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	3.2	242
470	The role of regional chemotherapy in the management of extremity soft tissue malignancies. <i>European Journal of Surgical Oncology</i> , 2016, 42, 7-17.	0.5	15
471	Cancer of Unknown Primary. , 2016, , .		7
472	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary</i> , 2016, 19, 82-92.	1.6	259
473	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
474	Modulation of T Cell Activation in Obesity. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 489-500.	2.5	17
475	Cancer immunotherapy â€” immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515
476	The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs. <i>Oncolimmunology</i> , 2017, 6, e1273300.	2.1	24
477	Synthetic lethality: emerging targets and opportunities in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 183-193.	1.5	12

#	ARTICLE	IF	CITATIONS
478	In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	390
479	Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross-sectional survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 815-820.	1.3	51
480	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
481	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. <i>European Journal of Cancer</i> , 2017, 73, 1-8.	1.3	397
482	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	0.8	458
483	Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy. <i>Advanced Biology</i> , 2017, 1, 1600013.	3.0	175
484	Checkpoint inhibition: new treatment options in urologic cancer. <i>Acta Clinica Belgica</i> , 2017, 72, 24-28.	0.5	13
485	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 417-427.	1.9	16
486	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	3.4	46
487	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44
488	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 428-439.	1.9	25
489	Novel immune check point inhibiting antibodies in cancer therapyâ€”Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	6.5	98
490	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <i>Cell Communication and Signaling</i> , 2017, 15, 1.	2.7	154
491	Is CD47 an innate immune checkpoint for tumor evasion?. <i>Journal of Hematology and Oncology</i> , 2017, 10, 12.	6.9	139
492	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	12.5	760
493	Tumor Microenvironment for Melanoma Cells. , 2017, , 357-368.		1
494	Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 209-216.	1.6	8
496	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126

#	ARTICLE	IF	CITATIONS
497	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	1.1	128
498	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117
499	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	1.1	32
500	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
501	Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2516-2527.	1.2	15
502	Nanomedicine as a potent strategy in melanoma tumor microenvironment. <i>Pharmacological Research</i> , 2017, 126, 31-53.	3.1	25
503	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 303-310.	3.3	12
504	Novel Therapies for Advanced Cervical Cancer. , 2017, , 263-299.		2
505	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 551-564.	2.0	253
506	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <i>Revue De Medecine Interne</i> , 2017, 38, 513-525.	0.6	36
507	Mouse genomic screen reveals novel host regulator of metastasis. <i>Genome Biology</i> , 2017, 18, 31.	3.8	3
508	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 44173.	1.6	70
509	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	1.4	4
510	Characterization of the Anti-“PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 861-870.	1.9	92
511	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38
512	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	1.8	85
513	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2017, 9, 261-272.	1.0	32
514	Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond. <i>Orl</i> , 2017, 79, 24-33.	0.6	6

#	ARTICLE	IF	CITATIONS
515	Combination immunotherapy: a road map. , 2017, 5, 16.		325
516	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, The, 2017, 18, e143-e152.	5.1	1,612
517	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nature Communications, 2017, 8, 14369.	5.8	192
518	Reactivation of dormant anti-tumor immunity â€“ a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling, 2017, 15, 5.	2.7	34
519	Immune checkpoint blockade for glioma. The Cochrane Library, 2017, , .	1.5	0
520	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. Current Hematologic Malignancy Reports, 2017, 12, 44-50.	1.2	12
521	LAG-3 Protein Expression in Nonâ€“Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192
522	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483
523	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. American Journal of Nephrology, 2017, 45, 160-169.	1.4	10,656
524	Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 2017, 1, .	11.6	178
525	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Current Oncology Reports, 2017, 19, 17.	1.8	30
526	Checkpoint Blockade in Lung Cancer and Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 274-282.	2.5	59
527	Timâ€“3 and its role in regulating antiâ€“tumor immunity. Immunological Reviews, 2017, 276, 97-111.	2.8	599
528	<sc>LAG</sc>3 (<sc>CD</sc>223) as a cancer immunotherapy target. Immunological Reviews, 2017, 276, 80-96.	2.8	664
529	Immunoregulatory functions of <sc>VISTA</sc>. Immunological Reviews, 2017, 276, 66-79.	2.8	154
530	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and metaâ€“analysis of published data. International Journal of Cancer, 2017, 141, 1018-1028.	2.3	116
531	Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma. JAMA Oncology, 2017, 3, 703.	3.4	5
532	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 344-351.	0.4	143

#	ARTICLE	IF	CITATIONS
533	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	2.0	125
534	Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma. <i>Nature Communications</i> , 2017, 8, .	5.8	103
535	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	2.7	83
536	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1069-1077.	0.4	58
537	Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 286-291.	1.6	49
539	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	1.8	18
540	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , 2017, 6, 139-151.	1.2	12
541	Rare heart risk found with checkpoint inhibitors. <i>Cancer</i> , 2017, 123, 1483-1484.	2.0	0
542	Age at cancer diagnosis may influence risk of heart disease death. <i>Cancer</i> , 2017, 123, 1484-1485.	2.0	0
543	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 597-611.	3.3	11
544	Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 294-303.	0.5	11
545	Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow in situ tumor vaccination?. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 833-840.	2.0	21
546	Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab. <i>American Journal of Dermatopathology</i> , 2017, 39, 23-27.	0.3	28
547	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. <i>American Journal of Surgical Pathology</i> , 2017, 41, 643-654.	2.1	146
548	Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 105.	6.9	129
549	Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. <i>Acta Oncologica</i> , 2017, 56, 1327-1330.	0.8	2
550	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	0.5	27
551	A Dose-Volume Response Model for Brain Metastases Treated With Frameless Single-Fraction Robotic Radiosurgery: Seeking to Better Predict Response to Treatment. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 344-351.	0.8	6

#	ARTICLE	IF	CITATIONS
552	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. <i>Clinical Lung Cancer</i> , 2017, 18, 682-691.e5.	1.1	74
553	Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4223-E4232.	3.3	121
554	Immunotherapy in advanced melanoma: a network meta-analysis. <i>Immunotherapy</i> , 2017, 9, 471-479.	1.0	9
555	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
556	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29
557	Personalized T cell-mediated cancer immunotherapy: progress and challenges. <i>Current Opinion in Biotechnology</i> , 2017, 48, 142-152.	3.3	78
558	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. <i>Cancer Research</i> , 2017, 77, 2318-2327.	0.4	235
559	Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890.		0
560	A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. <i>Cancer Medicine</i> , 2017, 6, 1143-1153.	1.3	60
561	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
562	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
563	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
564	MITF suppression by CH5552074 inhibits cell growth in melanoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1187-1193.	1.1	10
565	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncotarget</i> , 2017, 6, e1323161.	2.1	39
566	T-cell programming in pancreatic adenocarcinoma: a review. <i>Cancer Gene Therapy</i> , 2017, 24, 106-113.	2.2	45
567	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , The, 2017, 18, 31-41.	5.1	845
568	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81.	3.4	437
569	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 96-104.	1.5	19

#	ARTICLE	IF	CITATIONS
570	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1248-1260.	1.5	15
571	Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 31-35.	1.2	85
572	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	1.3	443
573	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
574	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 515-529.	0.6	16
575	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. <i>Oncologist</i> , 2017, 22, 709-718.	1.9	221
576	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. <i>Clinics in Chest Medicine</i> , 2017, 38, 223-232.	0.8	36
577	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
578	Adoptive T cell therapy: An overview of obstacles and opportunities. <i>Cancer</i> , 2017, 123, 2154-2162.	2.0	82
580	Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1560-1566.	2.8	73
581	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
582	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
583	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210
584	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. <i>Clinical Cancer Research</i> , 2017, 23, 5789-5801.	3.2	70
585	Immunotherapy: The Wave of the Future in Bladder Cancer?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, S3-S17.	0.9	8
586	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , 2017, 82, 56-65.	1.3	162
587	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
588	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. <i>Journal of Biomedical Science</i> , 2017, 24, 35.	2.6	88

#	ARTICLE	IF	CITATIONS
589	A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms. <i>European Journal of Dermatology</i> , 2017, 27, 184-185.	0.3	34
590	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. <i>Trends in Immunology</i> , 2017, 38, 577-593.	2.9	276
591	PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. <i>Nature Neuroscience</i> , 2017, 20, 917-926.	7.1	148
592	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 33.	1.3	13
593	Myeloid-derived suppressor cellsâ€”a new therapeutic target to overcome resistance to cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 727-740.	1.5	88
594	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. <i>Advanced Materials</i> , 2017, 29, 1606036.	11.1	220
595	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
596	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 153-164.	0.4	59
597	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	5.8	195
599	Assessment of programmed deathâ€”ligand 1 expression and tumorâ€”associated immune cells in pediatric cancer tissues. <i>Cancer</i> , 2017, 123, 3807-3815.	2.0	135
600	Drug-biomarker co-development in oncology â€” 20 years and counting. <i>Drug Resistance Updates</i> , 2017, 30, 48-62.	6.5	48
601	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
602	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672.	2.2	57
603	Research progress in advanced melanoma. <i>Cancer Letters</i> , 2017, 397, 120-126.	3.2	34
604	Beyond checkpoint inhibition â€” Immunotherapeutical strategies in combination with radiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 29-35.	0.9	27
605	Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. <i>World Neurosurgery</i> , 2017, 100, 632-640.e4.	0.7	48
606	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. <i>Pharmacological Research</i> , 2017, 120, 1-9.	3.1	46
607	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. <i>Scientific Reports</i> , 2017, 7, 45124.	1.6	72

#	ARTICLE	IF	CITATIONS
608	Adverse Events in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 155-174.	0.8	45
609	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.1	7
610	Masterful Antibodies: Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 275-281.	1.6	31
611	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
612	Unleashing the immune response against childhood solid cancers. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26548.	0.8	6
613	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
614	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485.	7.7	116
615	Recognizing and managing on toxicities in cancer immunotherapy. <i>Tumor Biology</i> , 2017, 39, 101042831769454.	0.8	27
617	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	2.7	35
618	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
619	Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 2952-2963.	0.4	86
621	The Role of Targeted Therapy in the Management of Sinonasal Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 443-455.	0.5	12
622	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <i>Biomarker Research</i> , 2017, 5, 12.	2.8	149
623	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. <i>Blood</i> , 2017, 129, 275-279.	0.6	85
624	Cutaneous adverse effects of the immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2017, 41, 125-128.	1.0	164
625	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
626	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	0.7	41
627	Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. <i>Clinical Endocrinology</i> , 2017, 86, 614-620.	1.2	165

#	ARTICLE	IF	CITATIONS
628	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
629	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2017, 29, 218-230.	0.6	49
630	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
631	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	3.0	56
632	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
633	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
634	Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 123, e188-e196.	0.2	22
635	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
636	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Onc Immunology</i> , 2017, 6, e1261242.	2.1	59
637	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	1.6	130
638	Cancer and inflammation. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1370.	6.6	166
639	Somatic Mutations and Neopeptide Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
640	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.4	163
641	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
642	Sepsis: Staging and Potential Future Therapies. <i>Colloquium Series on Integrated Systems Physiology From Molecule To Function</i> , 2017, 9, i-91.	0.3	0
643	Overexpression of immunomodulatory mediators in oral precancerous lesions. <i>Human Immunology</i> , 2017, 78, 752-757.	1.2	37
644	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	232
645	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220

#	ARTICLE	IF	CITATIONS
646	The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. <i>Lasers in Medical Science</i> , 2017, 32, 1935-1939.	1.0	2
647	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. <i>Clinical Skin Cancer</i> , 2017, 2, 24-31.	0.1	2
648	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
649	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	1.6	131
650	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. <i>Cellular Immunology</i> , 2017, 322, 1-14.	1.4	114
651	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	0.7	53
652	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 23-28.	2.0	17
653	A Blueprint to Advance Colorectal Cancer Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 942-949.	1.6	63
654	Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of) Tj ETQqO 0 0,rgBT /Overlock 10 TF	1.4	0
655	The evolutionary nature of the cancer immunotherapy revolution. <i>Future Oncology</i> , 2017, 13, 1565-1567.	1.1	4
656	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017, 28, 2860-2865.	0.6	115
657	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <i>Annals of Oncology</i> , 2017, 28, 3015-3021.	0.6	79
658	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	3.2	73
659	Survival of patients with advanced metastatic melanoma: the impact of novel therapiesâ€“update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	1.3	236
660	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. <i>BMJ Open</i> , 2017, 7, e014880.	0.8	18
661	Challenges faced when identifying patients for combination immunotherapy. <i>Future Oncology</i> , 2017, 13, 1607-1618.	1.1	10
662	Should we be combining local tumor therapies with immunotherapies as standard?. <i>Future Oncology</i> , 2017, 13, 1573-1575.	1.1	3
663	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920.	2.9	145

#	ARTICLE	IF	CITATIONS
664	Tumour radiosensitivity is associated with immune activation in solid tumours. <i>European Journal of Cancer</i> , 2017, 84, 304-314.	1.3	44
665	Trial watch: Immune checkpoint blockers for cancer therapy. <i>OncImmunology</i> , 2017, 6, e1373237.	2.1	62
666	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2561-2574.	1.4	91
667	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.3	58
668	Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. <i>Journal of Biological Chemistry</i> , 2017, 292, 18530-18541.	1.6	67
669	Novel Immunologic Approaches to Melanoma Treatment. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 708-720.	0.2	0
671	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
673	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	0.8	57
674	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
675	Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1523-1538.	1.4	13
676	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	1.4	56
677	Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	174
678	Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399.	1.1	2
679	CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. <i>Immunotherapy</i> , 2017, 9, 929-941.	1.0	34
680	Interprofessional Collaboration with Immune Checkpoint Inhibitor Therapy: the Roles of Gastroenterology, Endocrinology and Neurology. <i>Seminars in Oncology Nursing</i> , 2017, 33, 402-414.	0.7	5
681	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	3.2	14
682	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
683	Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination. <i>Melanoma Research</i> , 2017, 27, 485-491.	0.6	88

#	ARTICLE	IF	CITATIONS
684	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. <i>Oncology</i> , 2017, 93, 164-176.	0.9	6
685	Neurological Complications of Immunotherapies—Beware of the Checkpoint Ahead. <i>JAMA Neurology</i> , 2017, 74, 1176.	4.5	2
686	Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. <i>Cancer Medicine</i> , 2017, 6, 1923-1929.	1.3	39
687	Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. <i>Lancet Oncology</i> , The, 2017, 18, 1144-1145.	5.1	2
688	Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. <i>Annals of Oncology</i> , 2017, 28, 2318-2319.	0.6	33
689	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. <i>Clinical Skin Cancer</i> , 2017, 2, 10-17.	0.1	1
690	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	3.4	88
691	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	1.3	24
692	Novedades en inmunología del melanoma. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 708-720.	0.2	6
693	CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 199-205.	0.2	5
694	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 321-325.	0.6	46
695	Precision Medicine and PET/Computed Tomography in Melanoma. <i>PET Clinics</i> , 2017, 12, 449-458.	1.5	11
696	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. <i>International Journal of Cancer</i> , 2017, 141, 1891-1900.	2.3	23
698	Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 721-728.	0.2	0
699	Immunohistochemical investigations on the expression of programmed cell death ligand 1, human leukocyte antigens G and E, and granzyme B in intraoral mucoepidermoid carcinoma. <i>Archives of Oral Biology</i> , 2017, 83, 55-62.	0.8	24
700	METÁSTASIS CEREBRALES: UNA MIRADA BIOLÓGICA Y CLÍNICA. <i>Revista Médica Clínica Las Condes</i> , 2017, 28, 437-449.	0.2	1
701	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S26-S30.	0.2	5
702	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. <i>Current Oncology Reports</i> , 2017, 19, 62.	1.8	20

#	ARTICLE	IF	CITATIONS
703	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. <i>Annals of Oncology</i> , 2017, 28, 862-867.	0.6	13
704	PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 851-856.	0.7	21
705	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
706	Checkpoint inhibitors in the treatment of urological malignancies. <i>ESMO Open</i> , 2017, 2, e000165.	2.0	21
707	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
710	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 63-67.	1.0	8
711	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy—Summary of Advances and Future Directions for Studying These Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 3-9.	1.0	5
712	Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 59-62.	1.0	9
713	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515.	8.9	241
714	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862.	6.3	1,032
715	KEYNOTE-006: a success in melanoma, but a long way to go. <i>Lancet, The</i> , 2017, 390, 1816-1817.	6.3	1
716	Advances in the Immunobiological Therapies for Advanced Melanoma. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 721-728.	0.2	0
717	Clinical investigation of 38 cases of oral mucosal melanoma: A multicentre retrospective analysis in Japan. <i>Australasian Journal of Dermatology</i> , 2017, 58, e223-e227.	0.4	5
718	Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. <i>European Journal of Pediatrics</i> , 2017, 176, 1163-1172.	1.3	11
719	Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.	1.3	84
720	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
721	Immunotherapy for Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017, 57, 29-39.	0.3	10
722	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017, 28, 2377-2385.	0.6	631

#	ARTICLE	IF	CITATIONS
723	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341773156.	0.6	36
724	Advances in the Management of Melanoma. <i>Current Dermatology Reports</i> , 2017, 6, 288-296.	1.1	1
726	Checkpoint inhibition in pediatric hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 379-394.	0.3	23
727	Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction. <i>Immunity</i> , 2017, 47, 1114-1128.e6.	6.6	76
728	MELK Promotes Melanoma Growth by Stimulating the NF- κ B Pathway. <i>Cell Reports</i> , 2017, 21, 2829-2841.	2.9	61
729	The Pancreatic Cancer Microenvironment. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 321-325.	1.0	132
730	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology, The</i> , 2017, 18, e731-e741.	5.1	568
731	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	4.5	90
732	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. <i>Oncologist</i> , 2017, 22, 1470-1477.	1.9	10
734	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	0.8	36
735	Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. <i>Nature Communications</i> , 2017, 8, 1447.	5.8	67
736	New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. <i>Infectious Diseases and Therapy</i> , 2017, 6, 461-476.	1.8	18
737	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
738	A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 558-562.	1.5	31
739	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. <i>Journal of Immunology</i> , 2017, 199, 974-981.	0.4	5
740	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
741	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , 2017, 82, 155-166.	1.3	148
742	<sc>VEGF</sc> blockade enhances the antitumor effect of <sc> BRAF ^V </sc> ^{600E} inhibition. <i>EMBO Molecular Medicine</i> , 2017, 9, 219-237.	3.3	36

#	ARTICLE	IF	CITATIONS
743	The new paradigm of systemic therapies for metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 356-368.	0.6	34
744	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142.	0.6	1,744
745	Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine. <i>Spine</i> , 2017, 42, E721-E725.	1.0	11
747	Immunotheranostic Polymersomes Modularly Assembled from Tetrablock and Diblock Copolymers with Oxidation-Responsive Fluorescence. <i>Cellular and Molecular Bioengineering</i> , 2017, 10, 357-370.	1.0	21
748	Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. <i>European Journal of Cancer</i> , 2017, 81, 203-205.	1.3	38
749	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
750	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
751	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
752	Immunotherapeutic Approaches to Biliary Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 44.	1.3	8
753	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. <i>Medicine (United States)</i> , 2017, 96, e7325.	0.4	80
754	Endocrine dysfunction following immune checkpoint inhibitor therapy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 337-347.	1.2	18
755	PD-1 vs PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
756	The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. <i>Clinical Oncology</i> , 2017, 29, 153-160.	0.6	67
757	Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 771-781.	1.7	122
758	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
759	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
760	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
761	Immunotherapy in melanoma: Recent advances and future directions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 604-611.	0.5	216

#	ARTICLE	IF	CITATIONS
762	TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends in Immunology, 2017, 38, 20-28.	2.9	310
763	Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. JAMA Oncology, 2017, 3, 366.	3.4	68
764	Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. Breast Cancer Research and Treatment, 2017, 161, 51-62.	1.1	8
765	(Neo)adjuvant systemic therapy for melanoma. European Journal of Surgical Oncology, 2017, 43, 534-543.	0.5	52
766	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 132-140.	1.1	18
767	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	0.5	21
768	Local delivery of checkpoints antibodies. Human Vaccines and Immunotherapeutics, 2017, 13, 245-248.	1.4	16
769	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3214-3222.	3.2	44
770	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. Future Oncology, 2017, 13, 625-636.	1.1	31
771	Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology. Rheumatic Disease Clinics of North America, 2017, 43, 65-78.	0.8	101
772	Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America, 2017, 26, 133-142.	0.6	7
773	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	3.2	261
774	Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting. Clinical Journal of Oncology Nursing, 2017, 21, E260-E266.	0.3	4
775	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. Medicine (United States), 2017, 96, e8931.	0.4	21
776	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. Oncology, 2017, 93, 147-159.	0.9	83
777	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology, 2017, , .	0.8	9
778	Intratumoral immunotherapy: using the tumor as the remedy. Annals of Oncology, 2017, 28, xii33-xii43.	0.6	253
779	Preclinical and clinical development of neoantigen vaccines. Annals of Oncology, 2017, 28, xii11-xii17.	0.6	160

#	ARTICLE	IF	CITATIONS
780	Adaptive Resistance to Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 213-227.	0.8	15
781	Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 19-31.	0.8	212
782	Awakening immunity against cancer: a 2017 primer for clinicians. <i>Chinese Journal of Cancer</i> , 2017, 36, 67.	4.9	12
783	Hypophysitis: Nursing Management of Immune-Related Adverse Events. <i>Clinical Journal of Oncology Nursing</i> , 2017, 21, 154-156.	0.3	5
784	Die Systemtherapie des fortgeschrittenen Melanoms im Jahr 2016. <i>Karger Kompass Dermatologie</i> , 2017, 5, 126-133.	0.0	0
786	The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. <i>Annals of Research Hospitals</i> , 2017, 1, 1-1.	0.0	1
787	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	11
788	Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab. <i>Endocrine Practice</i> , 2017, 23, 1223-1231.	1.1	23
789	PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. <i>Oncotarget</i> , 2017, 8, 15894-15911.	0.8	84
790	Systemic Therapy Options for Patients With Unresectable Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 661-672.	1.8	8
791	Updated Landscape of the Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine. , 2017, , .		0
792	High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. <i>Blood Advances</i> , 2017, 1, 1306-1308.	2.5	20
793	Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: A case report. <i>Case Reports in Internal Medicine</i> , 2017, 4, 57.	0.0	0
794	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 325-339.	0.8	52
795	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 49.	1.6	459
796	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. <i>Journal of Cancer</i> , 2017, 8, 410-416.	1.2	176
797	Chemotherapy and Targeted Agents. , 2017, , 339-354.		3
798	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101

#	ARTICLE	IF	CITATIONS
799	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 28.	1.3	22
800	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1389-1399.	0.8	23
801	Treatment of advanced melanoma - A changing landscape. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 814-823.	0.3	15
802	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 73-82.	2.7	121
803	miRNAs, Melanoma and Microenvironment: An Intricate Network. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2354.	1.8	43
804	PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13
805	Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. <i>Frontiers in Immunology</i> , 2017, 8, 513.	2.2	19
806	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
807	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. <i>Frontiers in Immunology</i> , 2017, 8, 830.	2.2	54
808	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <i>Frontiers in Immunology</i> , 2017, 8, 1547.	2.2	125
809	Tregs: Where We Are and What Comes Next?. <i>Frontiers in Immunology</i> , 2017, 8, 1578.	2.2	142
810	Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1594.	2.2	48
811	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
812	Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca ²⁺ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK. <i>Frontiers in Oncology</i> , 2017, 7, 95.	1.3	22
813	The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. <i>Frontiers in Oncology</i> , 2017, 7, 190.	1.3	92
814	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	6
815	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. <i>Melanoma Management</i> , 2017, 4, 79-82.	0.1	0
816	Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 653-664.	0.5	61

#	ARTICLE	IF	CITATIONS
817	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15
818	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	0.9	128
819	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6
820	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. <i>PLoS ONE</i> , 2017, 12, e0177810.	1.1	23
821	Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. <i>Internal Medicine</i> , 2017, 56, 2463-2469.	0.3	34
822	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>Oncolimmunology</i> , 2017, 6, e1344805.	2.1	142
823	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
824	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. <i>Melanoma Management</i> , 2017, 4, 151-155.	0.1	2
825	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584.	1.1	11
826	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	6.9	92
827	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
828	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
829	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
830	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. <i>Chinese Journal of Cancer</i> , 2017, 36, 61.	4.9	42
831	Clinical safety of combined therapy of immune checkpoint inhibitors and <i>Viscum album L.</i> therapy in patients with advanced or metastatic cancer. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 534.	3.7	31
832	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. <i>Journal of Biomedical Sciences</i> , 2017, 06, .	0.3	0
833	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <i>Cancer Biology and Medicine</i> , 2017, 14, 341.	1.4	4
834	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4

#	ARTICLE	IF	CITATIONS
835	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
836	PD1 signal transduction pathways in T cells. <i>Oncotarget</i> , 2017, 8, 51936-51945.	0.8	191
837	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1175-1182.	2.0	14
838	An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma. <i>Vaccines</i> , 2017, 5, 38.	2.1	14
839	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. <i>Oncotarget</i> , 2017, 8, 100863-100898.	0.8	16
840	First-line treatment of metastatic melanoma: role of nivolumab. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 1-10.	2.7	26
841	Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347.	0.8	16
842	Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis. <i>The Journal of Critical Care Medicine</i> , 2017, 3, 84-88.	0.3	0
843	Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. <i>Oncotarget</i> , 2017, 8, 83637-83649.	0.8	7
844	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 674-683.	1.8	18
845	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	35
846	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
847	Can Prostate Cancer Really Respond to Immunotherapy?. <i>Journal of Clinical Oncology</i> , 2017, 35, 4-5.	0.8	6
848	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
849	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	0.8	244
850	Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3792-3793.	0.8	9
851	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	11
852	Hodgkin lymphoma and PD-1 blockade: an unfinished story. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	4

#	ARTICLE	IF	CITATIONS
853	Case Report of Extended Survival and Quality of Life in a Melanoma Patient with Multiple Brain Metastases and Review of Literature. <i>Cureus</i> , 2017, 9, e1947.	0.2	9
854	Locally advanced non-small cell lung cancer treatment: another step forward. <i>Journal of Thoracic Disease</i> , 2017, 9, 4908-4911.	0.6	4
855	Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. <i>Oncotarget</i> , 2017, 8, 98215-98232.	0.8	30
856	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	0.8	53
857	A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. <i>Oncotarget</i> , 2017, 8, 29067-29079.	0.8	29
858	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. <i>Oncolimmunology</i> , 2018, 7, e1440168.	2.1	31
859	Targeting the microenvironment in solid tumors. <i>Cancer Treatment Reviews</i> , 2018, 65, 22-32.	3.4	342
860	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF β 2 enhance the efficacy of cancer immunotherapy. <i>Nature Communications</i> , 2018, 9, 741.	5.8	238
861	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	2.8	96
862	Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. <i>Cancer Medicine</i> , 2018, 7, 991-996.	1.3	12
863	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 24.	1.8	35
864	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. <i>Cancer Medicine</i> , 2018, 7, 690-697.	1.3	90
866	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	2.0	15
867	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 20-27.	4.2	55
868	Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 217-231.	157.7	117
869	Melanoma Immunotherapy in the Elderly. <i>Current Oncology Reports</i> , 2018, 20, 20.	1.8	16
870	Dose-dependent toxicity of ipilimumab in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 95, 104-108.	1.3	6
871	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	3.2	73

#	ARTICLE	IF	CITATIONS
872	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. <i>Hla</i> , 2018, 92, 3-11.	0.4	10
873	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2018, 59, 328-338.	1.7	19
875	A Dual Immunotherapy Nanoparticle Improves Tâ€Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
876	Atezolizumab for the treatment of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 595-603.	1.4	17
877	Tissueâ€resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. <i>Immunological Reviews</i> , 2018, 283, 54-76.	2.8	142
878	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. <i>Nature Communications</i> , 2018, 9, 1538.	5.8	49
879	Cardioprotection in the Modern Era of Cancer Chemotherapy. <i>Cardiology in Review</i> , 2018, 26, 113-121.	0.6	9
880	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	2.0	15
881	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
882	The gut microbiota influences anticancer immunosurveillance and general health. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 382-396.	12.5	389
883	Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. <i>BioDrugs</i> , 2018, 32, 221-231.	2.2	22
884	Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-ÎB/IL-6/STAT3 axis. <i>Oncogene</i> , 2018, 37, 2456-2468.	2.6	54
886	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018, 93, 147-149.	1.3	10
888	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	3.3	131
889	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
890	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
891	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52
892	Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 149, 3-23.	1.0	28

#	ARTICLE	IF	CITATIONS
893	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. Cell Death and Disease, 2018, 9, 112.	2.7	94
894	Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/Tâ€œCL. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e252-e258.	0.7	12
895	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis, 2018, 7, 2.	2.1	68
896	Clinical Development of PD-1 in Advanced Melanoma. Cancer Journal (Sudbury, Mass), 2018, 24, 7-14.	1.0	37
897	The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cellular and Molecular Immunology, 2018, 15, 438-446.	4.8	88
898	Complete ophthalmoplegia in Ipilimumab and Nivolumab combination treatment for metastatic melanoma. Orbit, 2018, 37, 381-384.	0.5	13
899	Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775007.	1.0	88
900	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-Î². Science Translational Medicine, 2018, 10, .	5.8	386
901	The role of nivolumab in melanoma. Future Oncology, 2018, 14, 1241-1252.	1.1	12
902	Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 2018, 64, 11-20.	3.4	76
903	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	1.6	56
904	Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. Cancer Cell, 2018, 33, 322-336.e8.	7.7	103
905	The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2018, 41, 101-108.	1.2	57
910	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	5.1	486
911	First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Annals of Oncology, 2018, 29, 542-543.	0.6	16
912	Hypermutated Tumors and Immune Checkpoint Inhibition. Drugs, 2018, 78, 155-162.	4.9	22
913	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncology, The, 2018, 19, 416-426.	5.1	517
914	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open, 2018, 3, e000257.	2.0	62

#	ARTICLE	IF	CITATIONS
915	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8
916	Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 202-207.	2.0	43
917	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974.	0.8	26
918	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 141-152.	0.7	54
919	T cell exhaustion in cancer: Mechanisms and clinical implications. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4279-4286.	1.2	40
920	Interrater reliability for histopathologic diagnosis of keratinocyte carcinomas. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 185-187.	0.6	5
921	Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 45-53.	2.7	30
922	The biology and therapeutic management of melanoma brain metastases. <i>Biochemical Pharmacology</i> , 2018, 153, 35-45.	2.0	12
923	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
924	Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive "Cold" Tumors "Hot". <i>Trends in Cancer</i> , 2018, 4, 38-58.	3.8	130
925	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
926	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
927	BCG and Anti-PDL-1 Ab in Bladder Cancers. , 2018, , 357-369.		0
928	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
929	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. , 2018, , 565-578.		1
930	Checkpoint inhibitors in breast cancer " Current status. <i>Cancer Treatment Reviews</i> , 2018, 63, 122-134.	3.4	112
931	Dermatologic Reactions to Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 345-361.	3.3	426
932	Update on adjuvant melanoma therapy. <i>Current Opinion in Oncology</i> , 2018, 30, 118-124.	1.1	12

#	ARTICLE	IF	CITATIONS
933	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. <i>Journal of Immunotherapy</i> , 2018, 41, 86-95.	1.2	28
934	Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword. <i>British Journal of Haematology</i> , 2018, 181, 38-53.	1.2	42
935	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. <i>Clinical Cancer Research</i> , 2018, 24, 2268-2275.	3.2	116
936	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	2.9	944
937	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
938	The efficacy and safety of anti-PD-1 antibodies combined with chemotherapy or CTLA-4 antibody as a first-line treatment for advanced lung cancer. <i>International Journal of Cancer</i> , 2018, 142, 2344-2354.	2.3	47
939	State-of-the-Art Diagnosis and Treatment of Melanoma. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 331-339.	0.5	0
940	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. <i>International Immunology</i> , 2018, 30, 13-22.	1.8	74
941	Integration of radiation and immunotherapy in breast cancer - Treatment implications. <i>Breast</i> , 2018, 38, 66-74.	0.9	38
942	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304
943	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. <i>Oncolmmunology</i> , 2018, 7, e1421891.	2.1	57
944	The Basics of Cancer Immunotherapy. , 2018, , .		5
945	Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. , 2018, , 143-152.		1
946	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. <i>BMC Cancer</i> , 2018, 18, 302.	1.1	17
947	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. <i>Journal of Translational Medicine</i> , 2018, 16, 94.	1.8	132
948	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
949	Immunotherapy of Hepatocellular Carcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 292-297.	0.8	27
950	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.0	252

#	ARTICLE	IF	CITATIONS
951	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1204-1212.	0.5	46
952	Checkpoint blockade after kidney transplantation. <i>European Journal of Cancer</i> , 2018, 96, 111-114.	1.3	15
954	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1695-1705.	0.9	177
955	Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. <i>Clinical Cancer Research</i> , 2018, 24, 3409-3422.	3.2	44
956	A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. <i>Seminars in Oncology</i> , 2018, 45, 170-175.	0.8	17
958	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. <i>Oncology</i> , 2018, 94, 259-273.	0.9	15
959	Treatment Sequencing in Advanced BRAF-Mutant Melanoma Patients: Current Practice in the United States. <i>Journal of Pharmacy Technology</i> , 2018, 34, 17-23.	0.5	5
960	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
961	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
962	The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 66-74.	4.3	18
963	Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 469-473.	1.5	9
964	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 451-458.	0.5	19
965	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
966	Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. <i>Seminars in Oncology</i> , 2018, 45, 164-169.	0.8	58
967	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 2951-2962.	3.2	25
968	Melanoma and Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 29.	1.8	54
969	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Oncolimmunology</i> , 2018, 7, e1438106.	2.1	54
970	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476

#	ARTICLE	IF	CITATIONS
971	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
972	Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 211-221.	0.6	21
973	Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. <i>Radiotherapy and Oncology</i> , 2018, 127, 310-317.	0.3	22
974	Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 1-16.	1.0	2
975	PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. <i>British Journal of Haematology</i> , 2018, 180, 752-755.	1.2	18
976	Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e256-e257.	1.3	27
977	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	4.3	257
978	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , 2018, 25, 34-42.	1.3	88
979	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , 2018, 37, 187-195.	0.9	23
980	A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 640-649.	1.2	6
981	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 225-235.	0.6	61
982	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	0.6	304
983	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253
984	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	1.2	90
985	Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. <i>Journal of Dermatological Science</i> , 2018, 89, 60-66.	1.0	52
986	Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. <i>Journal of Dermatology</i> , 2018, 45, 3-9.	0.6	58
987	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
988	Safety of shortened infusion times for combined ipilimumab and nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 135-140.	2.0	3

#	ARTICLE	IF	CITATIONS
989	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Molecular Life Sciences, 2018, 75, 689-713.	2.4	351
990	PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. Oncoimmunology, 2018, 7, e1382792.	2.1	37
991	The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60.	0.9	10
992	Phosphatidylserine: A cancer cell targeting biomarker. Seminars in Cancer Biology, 2018, 52, 17-25.	4.3	128
993	PD-L1 inhibitors in the pipeline: Promise and progress. Oncoimmunology, 2018, 7, e1365209.	2.1	37
994	Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. Journal of Immunotherapy, 2018, 41, 39-41.	1.2	15
995	Targets for immunotherapy of liver cancer. Journal of Hepatology, 2018, 68, 157-166.	1.8	129
996	Neurological Complications of Immune-Based Therapies. , 2018, , 335-344.		0
997	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
998	Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 6-12.	0.6	25
999	Durvalumab in non-small-cell lung cancer patients: current developments. Future Oncology, 2018, 14, 205-222.	1.1	12
1000	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
1001	Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Current Problems in Cancer, 2018, 42, 49-58.	1.0	25
1002	The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. European Journal of Endocrinology, 2018, 178, 173-180.	1.9	111
1003	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clinical Cancer Research, 2018, 24, 870-881.	3.2	75
1004	Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182.	10.6	736
1005	Disseminated erythema with intense and selective inflammation of sweat gland and lichenoid drug eruption during nivolumab therapy. Journal of Dermatology, 2018, 45, e33-e34.	0.6	2
1006	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opinion on Investigational Drugs, 2018, 27, 55-70.	1.9	5

#	ARTICLE	IF	CITATIONS
1007	Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 184-185.	0.6	4
1008	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
1009	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38
1010	Surgical and Anatomic Considerations of Malignancies Affecting the Groin: Consideration for Melanoma. , 2018, , 63-74.		0
1011	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
1012	A systematic review and meta-analysis of utility estimates in melanoma. <i>British Journal of Dermatology</i> , 2018, 178, 384-393.	1.4	12
1014	Melanoma Immunotherapy. <i>Current Cancer Research</i> , 2018, , 307-331.	0.2	0
1015	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
1016	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317.	3.3	78
1017	A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma. <i>OncImmunology</i> , 2018, 7, e1386827.	2.1	3
1018	Ceritinib Enhances the Efficacy of Trametinib in <i>BRAF/NRAS</i> -Wild-Type Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 73-83.	1.9	18
1019	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 907-910.	1.6	45
1020	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	3.4	125
1021	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. <i>Neuroendocrinology</i> , 2018, 106, 89-100.	1.2	14
1022	Comparison of the common bacteria in human and mouse tumours using high-throughput sequencing. <i>Molecular Medicine Reports</i> , 2018, 17, 6717-6722.	1.1	3
1023	Checkpoint inhibitor-associated autoimmunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 781-802.	1.4	13
1024	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
1025	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	0.8	156

#	ARTICLE	IF	CITATIONS
1026	Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 759-762.	1.8	13
1027	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
1028	Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 13-19.	1.8	74
1029	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	0.8	483
1030	Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. Journal of Clinical Oncology, 2018, 36, 720-721.	0.8	13
1031	Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. Journal of Oncological Science, 2018, 4, 125-129.	0.1	2
1032	Approach and management of checkpoint inhibitor-related immune hepatitis. Journal of Gastrointestinal Oncology, 2018, 9, 220-224.	0.6	28
1033	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. Journal of Immunotherapy, 2018, 41, 332-335.	1.2	68
1034	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S433-S450.	0.6	15
1035	Identifying and managing the adverse effects of immune checkpoint blockade. Journal of Thoracic Disease, 2018, 10, S480-S489.	0.6	78
1036	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. Journal of Thoracic Disease, 2018, 10, S4282-S4295.	0.6	69
1037	Microbial marauders: pancreatic microbiota and its impact on carcinogenesis. Annals of Translational Medicine, 2018, 6, S63-S63.	0.7	2
1039	Possibilities for the Therapy of Melanoma: Current Knowledge and Future Directions. , 2018, , .		1
1040	Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Reports, 2018, 2018, bcr-2018-226089.	0.2	0
1041	Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis. Current Pharmaceutical Design, 2018, 23, 5301-5314.	0.9	6
1042	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. Journal of Oncology Practice, 2018, 14, 529-535.	2.5	41
1043	An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Reports, 2018, 51, 572-577.	1.1	4
1044	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40

#	ARTICLE	IF	CITATIONS
1045	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2018, 35, 195-292.	1.2	12
1047	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 363, k4226.	2.4	362
1048	The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis. <i>Frontiers in Medicine</i> , 2018, 5, 307.	1.2	27
1049	Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. <i>European Journal of Cancer</i> , 2018, 105, 114-126.	1.3	52
1050	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
1051	Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1293-1302.	1.0	14
1052	Combatting mucosal melanoma: recent advances and future perspectives. <i>Melanoma Management</i> , 2018, 5, MMT11.	0.1	75
1053	Management of immunotherapy toxicities in older adults. <i>Seminars in Oncology</i> , 2018, 45, 226-231.	0.8	25
1054	Combination of PD-1 blockade and RetroNectin [®] -activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. <i>Immunotherapy</i> , 2018, 10, 1315-1323.	1.0	6
1055	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	26
1056	Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1199-1207.	1.4	16
1057	Komplette Remission eines Patienten mit metastasierten Uveamelanom nach initialem Progress unter Immuntherapie mit Pembrolizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1376-1378.	0.4	0
1058	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 114.		41
1059	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). , 2018, 6, 115.		24
1060	Analysis of PD-1 related immune transcriptional profile in different cancer types. <i>Cancer Cell International</i> , 2018, 18, 218.	1.8	15
1061	How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 2941.	2.2	20
1062	Anticancer Therapies. , 0, , 604-616.		0
1063	Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2821.	2.2	76

#	ARTICLE	IF	CITATIONS
1064	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	1.1	31
1065	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
1066	Immune Checkpoint Inhibitors-Induced Hepatitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 159-164.	0.8	26
1069	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018, 7, 326.	0.8	47
1070	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. <i>Frontiers in Oncology</i> , 2018, 8, 532.	1.3	27
1071	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	1.6	59
1072	Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1997.	2.2	16
1073	Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. <i>Anticancer Research</i> , 2018, 38, 5569-5580.	0.5	42
1074	Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 466-479.	2.7	15
1075	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2018, 15, 116.	1.4	52
1077	Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1376-1378.	0.4	1
1078	Viral hepatitis, inflammation, and cancer: A lesson for autoimmunity. <i>Journal of Autoimmunity</i> , 2018, 95, 58-68.	3.0	31
1079	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880808.	1.4	10
1080	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 2374.	2.2	150
1081	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
1082	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
1083	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
1084	Nobel goes to immune checkpointâ€”Innovative cancer treatment by immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1445-1450.	2.3	3

#	ARTICLE	IF	CITATIONS
1085	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2018, 9, 1955.	2.2	24
1086	Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 370.	1.3	91
1087	Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. <i>Immunotherapy</i> , 2018, 10, 1241-1252.	1.0	19
1088	3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. <i>Lab on A Chip</i> , 2018, 18, 3129-3143.	3.1	185
1089	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52
1090	A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. <i>Cell</i> , 2018, 174, 1373-1387.e19.	13.5	729
1091	Development of shellfish allergy after exposure to dual immune checkpoint blockade. <i>Hepatic Oncology</i> , 2018, 5, HEPO2.	4.2	3
1092	The nephrotoxicity of immune checkpoint inhibitor-based combinations. <i>European Journal of Cancer</i> , 2018, 103, 274-278.	1.3	5
1093	Posttransfusion purpura with antibodies against human platelet antigen 4a following checkpoint inhibitor therapy: a case report and review of the literature. <i>Transfusion</i> , 2018, 58, 2265-2269.	0.8	9
1094	Roles of the RANK-RANK axis in antitumour immunity implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
1095	Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. <i>Melanoma Research</i> , 2018, 28, 371-379.	0.6	15
1096	Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248.		0
1097	Melanoma. <i>Lancet, The</i> , 2018, 392, 971-984.	6.3	1,016
1098	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolmunology</i> , 2018, 7, e1501137.	2.1	120
1099	Expert opinions on adrenal complications in immunotherapy. <i>Annales D'Endocrinologie</i> , 2018, 79, 539-544.	0.6	13
1100	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. <i>PLoS ONE</i> , 2018, 13, e0191926.	1.1	17
1101	Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. , 2018, 6, 83.		45
1102	DNA-loaded nano-adjuvant formed with a vitamin E-scaffold intracellular environmentally-responsive lipid-like material for cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2587-2597.	1.7	33

#	ARTICLE	IF	CITATIONS
1103	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 209-215.	2.0	29
1104	Immunotherapy in melanoma. <i>Immunotherapy</i> , 2018, 10, 987-998.	1.0	22
1105	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27389.	0.8	25
1106	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
1107	Immune Checkpoint Blockade and Immune Monitoring. , 0, , .		1
1108	Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal. <i>British Journal of Dermatology</i> , 2018, 179, 296-300.	1.4	39
1109	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
1110	Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. <i>Oncologist</i> , 2018, 23, 1236-1241.	1.9	20
1111	Prospects of Gene Therapy to Treat Melanoma. <i>Advances in Cancer Research</i> , 2018, 138, 213-237.	1.9	17
1112	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
1113	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	3.2	89
1114	The 2018 American Academy of Allergy, Asthma & Immunology Foundation Faculty Development awardees. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 67-70.	1.5	0
1116	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
1117	Severe neurologic complications of immune checkpoint inhibitors: a single-center review. <i>Journal of Neurology</i> , 2018, 265, 1636-1642.	1.8	49
1118	CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. <i>Clinical Cancer Research</i> , 2018, 24, 4976-4987.	3.2	79
1119	Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. <i>Melanoma Management</i> , 2018, 5, MMT01.	0.1	11
1120	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. <i>Annals of Oncology</i> , 2018, 29, 1727-1740.	0.6	20
1121	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76

#	ARTICLE	IF	CITATIONS
1122	The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade. , 2018, , 653-668.		0
1123	Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors. , 2018, , 693-705.		0
1125	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. British Journal of Cancer, 2018, 119, 339-346.	2.9	83
1126	Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of Immunology Research, 2018, 2018, 1-16.	0.9	89
1127	Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 51-66.	3.3	241
1128	Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Radiotherapy and Oncology, 2018, 128, 266-273.	0.3	48
1129	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	2.0	93
1130	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum, 2018, 2, pky021.	1.4	92
1131	Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treatment Reviews, 2018, 70, 75-87.	3.4	19
1132	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
1133	Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. , 2018, 6, 77.		36
1134	A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. BMC Medical Informatics and Decision Making, 2018, 18, 37.	1.5	5
1135	Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. Strahlentherapie Und Onkologie, 2018, 194, 873-875.	1.0	11
1136	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 925-930.	0.7	5
1137	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. Cancer Immunology, Immunotherapy, 2018, 67, 1571-1578.	2.0	35
1139	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
1140	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
1141	Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes. Drug Design, Development and Therapy, 2018, Volume 12, 2025-2038.	2.0	8

#	ARTICLE	IF	CITATIONS
1142	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
1143	Immunotherapy in Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 518-528.	0.7	31
1144	Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. <i>Seminars in Liver Disease</i> , 2018, 38, 242-251.	1.8	95
1145	Checks and Balances in Autoimmune Vasculitis. <i>Frontiers in Immunology</i> , 2018, 9, 315.	2.2	31
1146	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 44.	1.3	67
1147	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. <i>Frontiers in Oncology</i> , 2018, 8, 80.	1.3	40
1148	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
1149	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1480301.	2.1	48
1150	Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma. <i>Internal Medicine</i> , 2018, 57, 1789-1792.	0.3	26
1151	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
1152	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. <i>Journal of Clinical Medicine</i> , 2018, 7, 151.	1.0	11
1153	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
1154	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27313.	0.8	11
1155	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	425
1156	Wnt3a/Î²-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers. <i>Cancer Immunology Research</i> , 2018, 6, 941-952.	1.6	34
1157	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. <i>Oncologist</i> , 2018, 23, 1119-1126.	1.9	72
1158	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	1.6	60
1159	Cardiotoxicities associated with immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2018, 42, 422-432.	1.0	42

#	ARTICLE	IF	CITATIONS
1160	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
1161	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 285-318.	0.8	16
1162	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. <i>Molecular Imaging and Biology</i> , 2018, 20, 696-704.	1.3	30
1163	Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 171.	0.4	25
1165	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
1166	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. <i>Aids</i> , 2018, 32, 1491-1497.	1.0	136
1167	Tumor-Specific Inhibition of <i>In Situ</i> Vaccination by Distant Untreated Tumor Sites. <i>Cancer Immunology Research</i> , 2018, 6, 825-834.	1.6	61
1168	Recent Advances in the Histopathology of Drug-Induced Liver Injury. <i>Surgical Pathology Clinics</i> , 2018, 11, 297-311.	0.7	23
1169	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 653-664.	1.4	26
1170	Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2018, 63, 292-298.	1.7	83
1171	Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2018, 2018, 1-13.	0.6	3
1172	Autologous graft-versus-host disease with combined immune checkpoint blockade. <i>European Journal of Cancer</i> , 2018, 101, 275-277.	1.3	0
1173	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 285.	1.3	89
1174	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. <i>Nature Communications</i> , 2018, 9, 3196.	5.8	145
1175	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	3.2	152
1176	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251.	2.4	160
1177	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
1178	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0202725.	1.1	15

#	ARTICLE	IF	CITATIONS
1179	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
1180	Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity. <i>Cell Reports</i> , 2018, 24, 1790-1801.	2.9	35
1181	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
1182	Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. <i>Brachytherapy</i> , 2018, 17, 995-1003.	0.2	23
1183	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018, 69, 978-979.	1.8	0
1184	Engineering Platforms for T Cell Modulation. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 277-362.	1.6	8
1185	Expert opinion on thyroid complications in immunotherapy. <i>Annales D'Endocrinologie</i> , 2018, 79, 555-561.	0.6	33
1186	M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. <i>ACS Nano</i> , 2018, 12, 8977-8993.	7.3	286
1187	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
1188	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
1189	A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD(L)1 and Anti-CTLA-4 in Preclinical Models. <i>Cancer Immunology Research</i> , 2018, 6, 1136-1149.	1.6	151
1190	Nivolumab causes focal muscular inflammation without electrophysiological or muscle magnetic resonance imaging findings. <i>Neurology and Clinical Neuroscience</i> , 2018, 6, 112-114.	0.2	1
1191	Understanding Immune Tolerance of Cancer: Repurposing Insights from Fetal Allografts and Microbes. <i>BioEssays</i> , 2018, 40, e1800050.	1.2	8
1192	Immunobiology of the Melanoma Microenvironment. , 2018, , 133-142.		0
1193	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1261-1270.	2.0	22
1195	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
1196	Checkpoint blockade in esophagogastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 77-85.	0.8	9
1197	Non-conventional Inhibitory CD4+Foxp3+PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112

#	ARTICLE	IF	CITATIONS
1198	Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma. , 2018, , 85-96.		1
1199	Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecologic Oncology Reports, 2018, 25, 74-77.	0.3	42
1200	Immunotherapy of Cancer. , 2019, , 1033-1048.e1.		3
1201	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. Cardiology in Review, 2019, 27, 97-107.	0.6	19
1202	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrology Dialysis Transplantation, 2019, 34, 108-117.	0.4	137
1203	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. Journal of Geriatric Oncology, 2019, 10, 149-154.	0.5	14
1204	Acquired resistance to cancer immunotherapy. Seminars in Immunopathology, 2019, 41, 31-40.	2.8	34
1205	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 2019, 74, 49-60.	3.4	38
1206	Rash and Pruritus With PD-1 Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Pharmacology, 2019, 59, 45-54.	1.0	3
1207	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	1.4	3
1208	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	0.5	20
1209	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	4.8	57
1210	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Chemotherapy, 2019, 64, 62-80.	0.8	34
1211	Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. Journal of Comparative Effectiveness Research, 2019, 8, 461-473.	0.6	16
1212	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
1213	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
1214	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. , 2019, 7, 251513551986223.	1.4	28
1215	Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer, 2019, 8, 221-238.	4.2	51

#	ARTICLE	IF	CITATIONS
1216	Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. <i>Leukemia and Lymphoma</i> , 2019, 60, 3350-3362.	0.6	1
1218	The evolving landscape of immunotherapy in advanced prostate cancer. <i>Immunotherapy</i> , 2019, 11, 903-912.	1.0	22
1219	Natural melanoma-derived extracellular vesicles. <i>Seminars in Cancer Biology</i> , 2019, 59, 251-265.	4.3	32
1220	Potential Successes and Challenges of Targeted Cancer Therapies. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	0.9	26
1221	Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 ⁺ Cells. <i>Cell</i> , 2019, 178, 1189-1204.e23.	13.5	189
1222	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
1223	Kidney Complications of Immune Checkpoint Inhibitors: A Review. <i>American Journal of Kidney Diseases</i> , 2019, 74, 529-537.	2.1	55
1224	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
1225	Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems. <i>Polymers and Polymeric Composites</i> , 2019, , 1079-1134.	0.6	3
1226	Macroangiopathy is a positive predictive factor for response to immunotherapy. <i>Scientific Reports</i> , 2019, 9, 9728.	1.6	6
1227	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019, 51, 1074-1078.	0.4	32
1228	The Changing Clinical Spectrum of Hypophysitis. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 590-602.	3.1	35
1229	Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. <i>Targeted Oncology</i> , 2019, 14, 417-421.	1.7	34
1231	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019, 21, 76.	1.8	18
1232	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2019, 24, e1197-e1211.	1.9	15
1233	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 104-124.	6.6	14
1234	Cutaneous Melanoma in the Elderly: Review of a Growing Problem. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 434-447.	0.2	9
1235	Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. <i>Cell Research</i> , 2019, 29, 609-627.	5.7	74

#	ARTICLE	IF	CITATIONS
1236	Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. American Journal of Obstetrics and Gynecology, 2019, 221, 245.e1-245.e15.	0.7	22
1237	Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. , 2019, 7, 262.		12
1238	Monoclonal Antibodies in Dermatooncologyâ€”State of the Art and Future Perspectives. Cancers, 2019, 11, 1420.	1.7	9
1239	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 6709-6720.	3.2	32
1240	Advances in T-cell co-receptor biology and cancer immunotherapy. Seminars in Immunology, 2019, 42, 101281.	2.7	2
1241	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Management, 2019, 6, MMT20.	0.1	9
1242	Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. Journal of Oncology, 2019, 2019, 1-8.	0.6	9
1243	Endocrineâ€”related adverse events associated with immuneâ€”checkpoint inhibitors in patients with melanoma. Cancer Medicine, 2019, 8, 6585-6594.	1.3	31
1244	Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics, 2019, 9, 7924-7947.	4.6	77
1245	Peptide-based materials for cancer immunotherapy. Theranostics, 2019, 9, 7807-7825.	4.6	77
1246	Immune checkpoint inhibitorâ€”associated pituitaryâ€”adrenal dysfunction: A systematic review and metaâ€”analysis. Cancer Medicine, 2019, 8, 7503-7515.	1.3	35
1247	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. Journal of Oncology Practice, 2019, 15, e825-e834.	2.5	37
1248	The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Nonâ€”Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review. Frontiers in Pharmacology, 2019, 10, 1260.	1.6	18
1249	Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine, 2019, 48, 178-190.	2.7	66
1250	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32
1251	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. JNCI Cancer Spectrum, 2019, 3, pkz071.	1.4	4
1252	Japanese realâ€”world study of sequential nivolumab and ipilimumab treatment in melanoma. Journal of Dermatology, 2019, 46, 947-955.	0.6	11
1253	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. International Journal of Molecular Sciences, 2019, 20, 158.	1.8	29

#	ARTICLE	IF	CITATIONS
1254	Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. <i>Cancer Science</i> , 2019, 110, 3434-3441.	1.7	13
1255	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
1256	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
1257	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
1258	Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.		154
1259	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
1260	The Future of Immunotherapy in the Treatment of Cancer. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150934.	0.7	20
1261	STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. <i>Cancer Immunology Research</i> , 2019, 7, 1837-1848.	1.6	59
1262	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 225-240.	0.3	6
1263	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	0.8	52
1264	IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 397.	3.5	111
1266	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.2	2
1267	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
1268	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. <i>World Neurosurgery</i> , 2019, 130, 615-622.	0.7	13
1269	Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. <i>Future Oncology</i> , 2019, 15, 3665-3674.	1.1	14
1270	Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987091.	1.4	35
1271	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. <i>Current Oncology Reports</i> , 2019, 21, 2.	1.8	42
1272	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. <i>Melanoma Research</i> , 2019, 29, 301-310.	0.6	7

#	ARTICLE	IF	CITATIONS
1273	Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 172-177.	0.6	15
1274	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , 2019, 14, e0211112.	1.1	16
1275	The evolving role of immunology for the treatment of head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 62-69.	0.6	3
1276	Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 420-429.	0.7	12
1277	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. <i>Antibodies</i> , 2019, 8, 3.	1.2	22
1278	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. <i>European Journal of Cancer</i> , 2019, 109, 21-27.	1.3	188
1279	Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 1-11.	4.2	48
1280	Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 231-244.	1.5	71
1281	Combining immunotherapy and natural immune stimulants: mechanisms and clinical implications. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2633-2635.	1.2	1
1282	SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. <i>EBioMedicine</i> , 2019, 40, 151-162.	2.7	53
1283	Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. <i>Cancer Management and Research</i> , 2019, Volume 11, 3847-3860.	0.9	78
1284	Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-8.	0.2	15
1285	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 498.	1.3	33
1286	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
1287	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	3.2	83
1288	Probiotics <i>Lactobacillus reuteri</i> Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1235.	2.2	83
1289	Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?. <i>Annals of Oncology</i> , 2019, 30, 1448-1459.	0.6	146
1290	In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1. <i>Methods in Enzymology</i> , 2019, 629, 361-381.	0.4	19

#	ARTICLE	IF	CITATIONS
1291	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
1292	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 936-940.	15.2	246
1293	Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0216485.	1.1	36
1294	Pharmacoeigenetics of Acute Myeloid Leukemia. , 2019, , 541-549.		0
1295	Protein 4.1B Suppresses Tumor Metastasis by Regulating Epithelial-mesenchymal Transition Progression in Melanoma Cells. <i>International Journal of Medical Sciences</i> , 2019, 16, 529-536.	1.1	5
1296	Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1393-1405.	1.6	24
1297	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475
1298	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
1299	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
1300	The prognostic significance of the comprehensive complication index in patients with gastric cancer. <i>Surgery Today</i> , 2019, 49, 913-920.	0.7	10
1301	Cloxiquine, a traditional antituberculosis agent, suppresses the growth and metastasis of melanoma cells through activation of PPAR γ . <i>Cell Death and Disease</i> , 2019, 10, 404.	2.7	8
1302	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
1303	Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. <i>BMC Research Notes</i> , 2019, 12, 296.	0.6	6
1304	Targeting ERK beyond the boundaries of the kinase active site in melanoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 1551-1570.	1.3	26
1305	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
1306	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
1307	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
1308	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42

#	ARTICLE	IF	CITATIONS
1309	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e59-e69.	1.8	8
1310	Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. Tohoku Journal of Experimental Medicine, 2019, 248, 37-43.	0.5	5
1311	Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology, 2019, 19, 587-594.	0.5	62
1312	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. Expert Review of Molecular Diagnostics, 2019, 19, 517-529.	1.5	15
1313	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 2019, 16, 563-580.	12.5	1,235
1314	Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters, 2019, 457, 168-179.	3.2	148
1315	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
1316	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 999.	2.2	47
1317	Immune checkpoint inhibition for the treatment of mesothelioma. Expert Opinion on Biological Therapy, 2019, 19, 697-706.	1.4	18
1318	Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters, 2019, 456, 80-87.	3.2	36
1319	Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma. Clinical Pharmacology and Therapeutics, 2019, 106, 123-135.	2.3	6
1320	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunology Research, 2019, 7, 860-865.	1.6	76
1321	A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, 201, 103-119.		194
1322	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Advances in Cancer Research, 2019, 143, 63-144.	1.9	52
1323	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	2.2	177
1324	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. British Journal of Surgery, 2019, 106, 519-522.	0.1	35
1325	Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Current Oncology Reports, 2019, 21, 37.	1.8	72
1326	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clinical and Translational Oncology, 2019, 21, 1464-1471.	1.2	1

#	ARTICLE	IF	CITATIONS
1327	High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. <i>Biochemical Pharmacology</i> , 2019, 163, 458-471.	2.0	56
1328	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1111-1122.	1.4	297
1329	New emerging targets in cancer immunotherapy: the role of LAG3. <i>ESMO Open</i> , 2019, 4, e000482.	2.0	83
1330	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17
1331	Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. <i>Frontiers in Immunology</i> , 2019, 10, 9.	2.2	126
1332	CD56dim CD16 ⁺ Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- γ . <i>Frontiers in Immunology</i> , 2019, 10, 14.	2.2	41
1333	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2019, 33, 159-171.	2.2	40
1334	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
1335	Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	0.7	35
1336	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	3.9	151
1337	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
1338	Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy—Focus on Fc γ R1B. <i>Frontiers in Immunology</i> , 2019, 10, 481.	2.2	33
1339	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	1.6	16
1340	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 293-302.	0.9	27
1341	Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. <i>Stem Cells</i> , 2019, 37, 716-723.	1.4	25
1342	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 917-926.	2.0	59
1343	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. <i>Nature Medicine</i> , 2019, 25, 814-824.	15.2	293
1344	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79

#	ARTICLE	IF	CITATIONS
1345	Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 960-973.	3.7	24
1346	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
1347	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89.		108
1348	Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 167-178.	1.2	8
1349	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 355.e21-355.e29.	0.8	64
1350	From waterfall plots to spaghetti plots in early oncology clinical development. <i>Pharmaceutical Statistics</i> , 2019, 18, 526-532.	0.7	8
1351	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
1352	Immunological Agents Used in Cancer Treatment. <i>Eurasian Journal of Medicine</i> , 2019, 51, 90-94.	0.2	32
1353	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
1354	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
1355	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. <i>Immunotherapy</i> , 2019, 11, 591-598.	1.0	9
1356	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982709.	0.8	2
1357	Emerging Nano- and Microapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.	5.6	136
1358	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. <i>Cancer Treatment Reviews</i> , 2019, 74, 43-48.	3.4	38
1359	Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. <i>PLoS ONE</i> , 2019, 14, e0211866.	1.1	16
1360	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). <i>Oncology Letters</i> , 2019, 17, 2583-2591.	0.8	16
1361	Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. <i>Digestive Diseases and Sciences</i> , 2019, 64, 685-688.	1.1	1
1362	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221.	1.0	122

#	ARTICLE	IF	CITATIONS
1363	Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems. <i>Polymers and Polymeric Composites</i> , 2019, , 1-56.	0.6	1
1364	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
1365	Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. <i>Oncolmunology</i> , 2019, 8, e1571390.	2.1	1
1366	<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 211-221.	0.9	42
1367	Computational Analysis of Epigenetic Modifications in Melanoma. , 2019, , 327-342.		1
1368	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
1369	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 108.	2.2	117
1370	Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1402-1411.	0.5	15
1371	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
1372	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
1373	Long-Term Survival After Brain and Spine Metastasis in Malignant Melanoma. <i>World Neurosurgery</i> , 2019, 125, 164-169.	0.7	3
1374	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <i>Nature Reviews Cardiology</i> , 2019, 16, 325-343.	6.1	65
1375	Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy. , 2019, , .		0
1376	Immunotherapy for Treatment of Cancer. , 2019, , .		4
1377	Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, MÃ©dica Sur Hospital. <i>Wspolczesna Onkologia</i> , 2019, 23, 239-246.	0.7	0
1378	Current and Future Treatment Strategies for Rhabdomyosarcoma. <i>Frontiers in Oncology</i> , 2019, 9, 1458.	1.3	100
1379	Toxicity of tumor immune checkpoint inhibitorsâ€”more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	1.3	7
1380	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	1.9	36

#	ARTICLE	IF	CITATIONS
1381	Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2019, 9, 8332-8343.	4.6	31
1382	Incidence and Clinical Impact of Anti-TNF α Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolite Survey. <i>Journal of Immunotherapy</i> , 2019, 42, 175-179.	1.2	57
1384	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.3	6
1385	Co-signal Molecules in T Cell Activation. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	6
1386	Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 201-213.	2.0	20
1387	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
1388	Melanoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 543-553.	0.7	1
1389	Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 51-54.	1.2	16
1390	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
1391	Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit. <i>International Ophthalmology Clinics</i> , 2019, 59, 13-26.	0.3	9
1392	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75
1393	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
1394	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <i>Liver Cancer</i> , 2019, 8, 413-426.	4.2	40
1395	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	1.8	57
1396	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
1397	Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 50-52.	0.4	37
1398	Hyperthermia and immunotherapy: clinical opportunities. <i>International Journal of Hyperthermia</i> , 2019, 36, 4-9.	1.1	51
1399	Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. <i>Melanoma Research</i> , 2019, 29, 328-332.	0.6	6

#	ARTICLE	IF	CITATIONS
1400	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464.	0.6	26
1401	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2019, 30, 1052-1054.	0.7	3
1402	A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma. <i>Melanoma Research</i> , 2019, 29, 13-18.	0.6	1
1403	Impact of initial stage on metastatic melanoma survival. <i>Melanoma Research</i> , 2019, 29, 281-288.	0.6	12
1404	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	1.0	29
1405	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 1313-1325.	2.0	288
1406	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
1407	Immune Checkpoints. , 2019, , 19-43.		0
1408	CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 149-159.	1.9	21
1409	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. <i>Lung Cancer</i> , 2019, 130, 59-66.	0.9	65
1410	Combined Nivolumab and Ipilimumab Is an Effective Treatment for Melanoma Brain Metastases. <i>Neurosurgery</i> , 2019, 84, E134-E135.	0.6	2
1411	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	1.0	24
1412	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
1413	Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261.	0.8	14
1414	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. <i>European Journal of Cancer</i> , 2019, 107, 1-7.	1.3	48
1415	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
1416	Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 181-192.	1.0	13
1417	A non-functional neoepitope specific CD8 ⁺ T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . <i>OncImmunology</i> , 2019, 8, 1553478.	2.1	16

#	ARTICLE	IF	CITATIONS
1418	PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 443-448.	0.5	18
1419	Time to abandon single-site irradiation for inducing abscopal effects. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 123-135.	12.5	233
1420	Cutaneous Melanoma—A Review in Detection, Staging, and Management. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 25-38.	0.9	85
1421	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 297-303.	2.0	45
1422	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	2.0	48
1423	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	3.2	249
1424	¹⁸ F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 335-341.	2.8	123
1425	Immunotherapies and Novel Combinations. , 2019, , 643-653.		0
1426	Cancer immunotherapy of patients with HIV infection. <i>Clinical and Translational Oncology</i> , 2019, 21, 713-720.	1.2	22
1427	Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 26-30.	0.7	18
1428	Regulatory mechanisms of T cell activation—From basic research discoveries to a new principle of cancer therapy and the Nobel Prize. <i>Acta Physiologica</i> , 2019, 225, e13224.	1.8	2
1429	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
1430	Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 411.	3.4	63
1431	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 458-465.	1.6	43
1432	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2560-2574.	3.2	369
1433	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	1.1	20
1434	Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma—In Canada. <i>Pharmacoeconomics - Open</i> , 2019, 3, 321-331.	0.9	9
1435	Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. <i>International Immunopharmacology</i> , 2019, 68, 131-136.	1.7	14

#	ARTICLE	IF	CITATIONS
1436	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1692-1697.	3.3	237
1437	Radiotherapy and immunotherapy: a synergistic effect in cancer care. Medical Journal of Australia, 2019, 210, 47-53.	0.8	53
1438	Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunology, 2019, 20, 4.	0.9	149
1439	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Cancer, 2019, 125, 278-289.	2.0	24
1440	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	3.4	295
1441	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. Investigational New Drugs, 2019, 37, 799-809.	1.2	4
1442	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
1443	Immune dysregulation in cancer patients developing immune-related adverse events. British Journal of Cancer, 2019, 120, 63-68.	2.9	126
1444	Tumour cell-intrinsic <i>CTLA4</i> regulates <i>PD-1</i> expression in non-small cell lung cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 535-542.	1.6	68
1445	Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 85-95.	2.0	32
1446	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clinical Cancer Research, 2019, 25, 1196-1205.	3.2	85
1447	What's New in Dermatopathology: Inflammatory Dermatoses. Advances in Anatomic Pathology, 2019, 26, 40-55.	2.4	2
1448	Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Pharmacogenomics, 2019, 20, 113-127.	0.6	9
1449	Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology, 2019, 1904, 11-51.	0.4	25
1450	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. International Immunopharmacology, 2019, 67, 160-175.	1.7	33
1452	Interplay between small and long non-coding <i>RNA</i> s in cutaneous melanoma: a complex jigsaw puzzle with missing pieces. Molecular Oncology, 2019, 13, 74-98.	2.1	29
1453	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 930-939.	3.3	75
1454	Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Acta Dermato-Venereologica, 2019, 99, 206-210.	0.6	22

#	ARTICLE	IF	CITATIONS
1455	Immune checkpoint blockade opens a new way to cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 8541-8549.	2.0	84
1456	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0
1457	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. <i>Oncoimmunology</i> , 2019, 8, e1512329.	2.1	53
1458	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
1459	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
1460	Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. <i>Arthritis Care and Research</i> , 2019, 71, 362-366.	1.5	75
1461	Prognostic Significance of Pre- and Postoperative Lymphocyte Counts in Patients with Gastric Cancer. <i>Digestive Surgery</i> , 2019, 36, 137-143.	0.6	21
1462	Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 59-70.	0.8	9
1463	Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Pathology and Oncology Research</i> , 2020, 26, 317-325.	0.9	20
1464	Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 1025-1035.	2.0	95
1465	Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 854-859.	1.0	52
1466	Cancer Immunology. , 2020, , 84-96.e5.		0
1467	Pulmonary Complications of Anticancer Treatment. , 2020, , 715-724.e2.		1
1468	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 440-459.	0.6	37
1469	Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 986-994.	0.6	2
1470	Tumor Liquid Biopsies. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	11
1471	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
1472	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 184-193.	2.0	32

#	ARTICLE	IF	CITATIONS
1473	The postoperative platelet distribution width is useful for predicting the prognosis in patients with esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2020, 50, 123-133.	0.7	8
1474	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.	1.9	87
1475	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
1476	Management of Locoregionally Advanced Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 109-125.	0.5	5
1477	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	0.5	4
1478	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020, 95, 149-160.	1.1	6
1479	The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. <i>Journal of Pharmacy Practice</i> , 2020, 33, 338-349.	0.5	9
1480	Epstein-Barr Virus-Positive Mucocutaneous Ulcers Complicate Colitis Caused by Immune Checkpoint Regulator Therapy and Associate With Colon Perforation. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1785-1795.e3.	2.4	15
1481	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
1483	Something old, something new: liver injury associated with total parenteral nutrition therapy and immune checkpoint inhibitors. <i>Human Pathology</i> , 2020, 96, 39-47.	1.1	17
1484	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	1.5	51
1485	Dissimilar Appearances Are Deceptive—Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. <i>Cells</i> , 2020, 9, 114.	1.8	14
1486	<p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 321-328.	1.0	25
1487	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	1.0	120
1488	Precision Medicine in the Treatment of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 1-13.	0.6	7
1489	CCR2 inhibition reduces tumor myeloid cells and unmask a checkpoint inhibitor effect to slow progression of resistant murine gliomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1129-1138.	3.3	203
1490	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	0.7	39
1491	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111876.	2.6	98

#	ARTICLE	IF	CITATIONS
1492	Programmed Cell Death-1/Ligand-1 PET Imaging. <i>PET Clinics</i> , 2020, 15, 35-43.	1.5	34
1493	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 114-122.	4.3	45
1494	Lung Metastases. , 2020, , 831-845.e6.		3
1496	A case of non-small cell lung cancer with long-term response after re-challenge with nivolumab. <i>Respiratory Medicine Case Reports</i> , 2020, 29, 100979.	0.2	4
1497	Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 4-12.	4.0	82
1498	CT and MRI findings in leptomeningeal melanocytosis. <i>Radiology Case Reports</i> , 2020, 15, 186-189.	0.2	4
1499	Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. <i>Melanoma Research</i> , 2020, 30, 219-222.	0.6	3
1500	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
1501	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
1502	The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. <i>Melanoma Research</i> , 2020, 30, 85-101.	0.6	5
1503	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 70-80.	1.6	47
1504	Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?. <i>Annual Review of Cancer Biology</i> , 2020, 4, 241-256.	2.3	119
1505	New avenues for melanoma immunotherapy: Natural Killer cells?. <i>Scandinavian Journal of Immunology</i> , 2020, 91, e12861.	1.3	13
1506	Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. <i>Cancer Research</i> , 2020, 80, 798-810.	0.4	22
1507	Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. <i>Nanomedicine</i> , 2020, 15, 77-92.	1.7	38
1508	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <i>Cardio-Oncology</i> , 2020, 6, 21.	0.8	14
1509	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
1510	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8

#	ARTICLE	IF	CITATIONS
1511	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
1512	Strategies in DNA vaccine for melanoma cancer. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 869-891.	1.5	20
1513	Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 616.	2.1	47
1514	Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. <i>Current Problems in Cancer Case Reports</i> , 2020, 1, 100014.	0.1	2
1515	Predictive molecular markers in the era of immunotherapy. <i>Journal of Pancreatology</i> , 2020, 3, 132-138.	0.3	5
1516	SSAT State-of-the-Art Conference: Advancements in the Microbiome. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1885-1895.	0.9	1
1517	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106971.	1.7	7
1518	Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors. <i>Medicine (United States)</i> , 2020, 99, e21273.	0.4	9
1519	Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1544-1563.	2.9	29
1521	The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8689.	1.8	38
1522	Prognostic Role of Tumor Mutation Burden Combined With Immune Infiltrates in Skin Cutaneous Melanoma Based on Multi-Omics Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 570654.	1.3	16
1523	Eventos adversos gastrointestinales y hepáticos. , 2020, , .		0
1524	Eventos adversos dermatológicos. , 2020, , .		0
1525	Eventos adversos pulmonares. , 2020, , .		0
1526	Eventos adversos menos frecuentes. , 2020, , .		0
1527	Eventos adversos relacionados con el sistema endocrino. , 2020, , .		0
1528	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. <i>Seminars in Cancer Biology</i> , 2022, 86, 1033-1057.	4.3	14
1529	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20

#	ARTICLE	IF	CITATIONS
1530	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
1531	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
1532	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 36.	1.0	26
1533	Clinical Challenges of Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 38, 326-333.	7.7	286
1534	Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2020, 10, 1163.	1.3	7
1535	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	157.7	507
1536	Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094092.	1.4	11
1537	Immune-Checkpoint Blockade Therapy in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5456.	1.8	24
1538	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
1539	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020, 87, 106770.	1.7	7
1540	Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model. <i>Frontiers in Immunology</i> , 2020, 11, 1514.	2.2	23
1541	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	0.9	24
1542	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28
1543	Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection. <i>Molecular Therapy</i> , 2020, 28, 1795-1805.	3.7	4
1544	Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 1267-1275.	0.6	15
1545	Novel Approaches to the Systemic Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 104.	1.8	9
1546	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
1547	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 178-185.	0.7	17

#	ARTICLE	IF	CITATIONS
1548	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	0.8	69
1549	Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance. <i>Journal of Surgical Oncology</i> , 2020, 122, 1770-1777.	0.8	23
1550	Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. <i>Melanoma Research</i> , 2020, 30, 492-499.	0.6	3
1551	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992.		4
1552	Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 1257-1266.	0.6	16
1553	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. <i>Cancers</i> , 2020, 12, 2429.	1.7	5
1554	An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. <i>Cancer Medicine</i> , 2020, 9, 7863-7878.	1.3	4
1555	Safety of pembrolizumab for resected stage III melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1221-1227.	1.0	3
1556	The science and medicine of human immunology. <i>Science</i> , 2020, 369, .	6.0	147
1557	Editorial Comment to Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 179-180.	0.1	0
1558	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634.	1.7	7
1559	Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. <i>British Journal of Ophthalmology</i> , 2021, 105, 1263-1271.	2.1	36
1560	Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 141.	7.1	34
1561	Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 176-179.	0.1	1
1562	Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. <i>Acta Oncologica</i> , 2020, 59, 1447-1454.	0.8	18
1563	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
1564	Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. <i>Current Oncology</i> , 2020, 27, 204-214.	0.9	6
1565	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	0.7	8

#	ARTICLE	IF	CITATIONS
1566	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271.		29
1567	Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. <i>ESMO Open</i> , 2020, 5, e000585.	2.0	23
1568	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	1.7	45
1569	Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 601497.	2.2	21
1570	Hyperacute Onset of Immune Checkpoint Inhibitor-Related Acute Interstitial Nephritis. <i>Kidney International Reports</i> , 2020, 5, 2084-2088.	0.4	3
1571	MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. <i>OncImmunology</i> , 2020, 9, 1846915.	2.1	42
1572	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	18
1573	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9300.	1.8	23
1574	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
1575	Immune Therapy for Central Nervous System Metastasis. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 627-639.	0.8	0
1576	Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1769-1777.	1.1	25
1577	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
1578	Scientifically based combination therapies with immunoncology checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
1579	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
1580	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. , 2020, 8, e000146.		49
1581	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
1582	PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. <i>Frontiers in Pharmacology</i> , 2020, 11, 722.	1.6	65
1583	HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 877-888.	2.1	25

#	ARTICLE	IF	CITATIONS
1584	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
1585	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
1586	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
1587	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
1588	Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 783.	2.2	78
1589	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	0.4	19
1591	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	8
1592	Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431.	0.6	1
1593	Role of Surgery in Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 485-495.	0.6	8
1594	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. <i>European Journal of Cancer Care</i> , 2020, 29, e13268.	0.7	4
1595	CEACAM1 regulates CD8+ T cell immunity and protects from severe pathology during <i>Citrobacter rodentium</i> induced colitis. <i>Gut Microbes</i> , 2020, 11, 1790-1805.	4.3	8
1596	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 74.	6.9	17
1597	Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61.	2.2	1,022
1598	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	0.4	16
1599	Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. <i>Autoimmunity Reviews</i> , 2020, 19, 102587.	2.5	20
1600	Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma. <i>European Journal of Ophthalmology</i> , 2021, 31, 1391-1398.	0.7	9
1601	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1455-1489.	1.5	22
1602	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. <i>Cancer</i> , 2020, 126, 3758-3767.	2.0	37

#	ARTICLE	IF	CITATIONS
1603	Melanoma brain metastases: is it time to eliminate radiotherapy?. <i>Journal of Neuro-Oncology</i> , 2020, 149, 27-33.	1.4	6
1604	HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?. <i>Pharmacoeconomics - Open</i> , 2020, 4, 529-539.	0.9	3
1605	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	1.1	20
1606	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
1607	A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 435-445.	1.0	5
1608	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
1609	Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. <i>Anticancer Research</i> , 2020, 40, 1201-1218.	0.5	40
1610	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1392-1396.	1.2	31
1611	Pulmonary Administration: Strengthening the Value of Therapeutic Proximity. <i>Frontiers in Medicine</i> , 2020, 7, 50.	1.2	11
1612	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	1.1	13
1613	Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?. <i>JCO Oncology Practice</i> , 2020, 16, e779-e790.	1.4	3
1614	TGF-beta: a master immune regulator. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 427-438.	1.5	101
1615	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73
1616	Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer. <i>Biomolecules</i> , 2020, 10, 382.	1.8	8
1617	Investigative therapy for advanced esophageal cancer using the option for combined immunotherapy and chemotherapy. <i>Immunotherapy</i> , 2020, 12, 697-703.	1.0	5
1618	Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 32.	2.0	0
1619	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
1620	Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 592.	2.0	23

#	ARTICLE	IF	CITATIONS
1621	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	1.3	35
1622	Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity. <i>Molecular Oncology</i> , 2020, 14, 1930-1946.	2.1	21
1623	CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma. <i>Scientific Reports</i> , 2020, 10, 10768.	1.6	31
1624	Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	1.4	1
1625	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <i>Human Molecular Genetics</i> , 2020, 29, R186-R196.	1.4	7
1626	A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy. <i>Nano-Micro Letters</i> , 2020, 12, 142.	14.4	156
1627	Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma. <i>Immunological Medicine</i> , 2021, 44, 136-141.	1.4	11
1628	PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	111
1629	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
1630	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
1631	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
1632	Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. <i>Experimental Biology and Medicine</i> , 2020, 245, 1104-1114.	1.1	13
1633	The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 150.	0.8	30
1634	Orthopaedic Manifestations of Melanoma and Their Management. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2020, 28, e540-e549.	1.1	1
1635	Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. <i>Journal of Neuro-Oncology</i> , 2020, 149, 113-122.	1.4	38
1636	GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models. <i>Scientific Reports</i> , 2020, 10, 11003.	1.6	24
1637	Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review. <i>American Journal of Transplantation</i> , 2020, 20, 2457-2465.	2.6	86
1638	Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 6942-6953.	2.0	8

#	ARTICLE	IF	CITATIONS
1639	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with \pm Particle-Emitting Ultrasmall Silica Nanoparticles. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 459-473.	0.7	13
1640	Recognition and management of the gastrointestinal and hepatic immune-related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 95-102.	0.7	6
1641	Checkpoint Inhibitor-Induced Colitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 202-210.	0.2	68
1642	Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1671.	1.6	40
1643	IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. <i>Cancer Letters</i> , 2020, 477, 19-30.	3.2	47
1644	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. <i>Translational Oncology</i> , 2020, 13, 100738.	1.7	173
1645	Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 294-296.	13.9	19
1646	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.5	140
1647	Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5449-5460.	2.0	42
1648	Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2020, 38, 150-157.	0.6	11
1649	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	0.8	8
1650	Cancer immunotherapy through the prism of adaptation: Will Achilles catch the tortoise?. <i>Medical Hypotheses</i> , 2020, 137, 109545.	0.8	0
1651	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. <i>Nature Communications</i> , 2020, 11, 524.	5.8	29
1652	The miRNAs Role in Melanoma and in Its Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 878.	1.8	50
1653	Using personalized immune-humanized xenograft mouse models to predict immune checkpoint responses in malignant melanoma: potential and hurdles. <i>Annals of Oncology</i> , 2020, 31, 167-168.	0.6	3
1654	Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study. <i>Journal of Geriatric Oncology</i> , 2020, 11, 515-522.	0.5	31
1655	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	1.0	10
1656	Regulation of immune cell metabolism by cancer cell oncogenic mutations. <i>International Journal of Cancer</i> , 2020, 147, 307-316.	2.3	3

#	ARTICLE	IF	CITATIONS
1657	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
1658	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. <i>Journal of Leukocyte Biology</i> , 2020, 108, 363-376.	1.5	40
1659	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. <i>Gastroenterology</i> , 2020, 159, 609-623.	0.6	100
1660	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	3.3	42
1661	Rechallenge with checkpoint inhibitors in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 429-436.	0.4	17
1662	<p>Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2459-2469.	0.9	16
1663	Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2020, 6, 865.	3.4	295
1664	Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 487-493.	2.3	33
1666	Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current Evidence. <i>Drugs and Aging</i> , 2020, 37, 411-423.	1.3	3
1667	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
1668	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
1669	TNF-Î± inhibitor reduces drug-resistance to anti-PD-1: A mathematical model. <i>PLoS ONE</i> , 2020, 15, e0231499.	1.1	9
1670	PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. <i>BMC Cancer</i> , 2020, 20, 277.	1.1	34
1671	Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2286.	1.8	61
1672	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a realâ€world setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 105-115.	1.3	9
1673	A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. <i>Leukemia</i> , 2021, 35, 777-786.	3.3	78
1674	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
1675	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	1.5	11

#	ARTICLE	IF	CITATIONS
1676	Efficacy of immune checkpoint inhibitors in different types of melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4-13.	1.4	19
1677	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	7.7	145
1678	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	2.0	22
1679	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	3.2	222
1680	Identification of immune-related genes with prognostic significance in the microenvironment of cutaneous melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 943-959.	1.4	8
1681	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 395-403.	0.6	53
1682	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e129-e138.	1.0	2
1683	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14
1684	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	0.7	1
1685	Current status of cancer immunotherapy for gynecologic malignancies. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 167-172.	0.6	16
1686	Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 654-659.	0.2	10
1687	Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. <i>Protein Expression and Purification</i> , 2021, 177, 105766.	0.6	7
1688	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021, 26, 231-241.	1.9	29
1689	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1089-1099.	2.0	3
1690	Combinatorial Approaches to the Treatment of Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 145-158.	0.9	5
1691	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <i>British Journal of Radiology</i> , 2021, 94, 20200663.	1.0	13
1692	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	4.2	50
1693	Current status and future perspectives of immunotherapy in bladder cancer treatment. <i>Science China Life Sciences</i> , 2021, 64, 512-533.	2.3	21

#	ARTICLE	IF	CITATIONS
1694	Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. <i>Oncology & Hematology Review</i> , 2021, 16, 90.	0.2	0
1695	Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. <i>Journal of Immunotherapy</i> , 2021, 44, 63-70.	1.2	22
1696	Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma. <i>Oncotarget</i> , 2021, 12, 66-80.	0.8	3
1697	Radioimmunotherapy: future prospects from the perspective of brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 458-467.	0.4	6
1698	Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?. <i>Karger Kompass Dermatologie</i> , 2021, 9, 114-128.	0.0	0
1699	Predictors for the development of immune-mediated adverse events during treatment with immune checkpoint inhibitors. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 55.	0.0	0
1700	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	4.6	19
1701	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. <i>Korean Journal of Radiology</i> , 2021, 22, 584.	1.5	12
1702	Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence. , 2021, 9, e001660.		10
1703	Therapeutic strategies. , 2021, , 139-154.		0
1704	Immunotherapy in Immunosuppressed Patients. , 2021, , 429-440.		0
1705	Industrial Perspective on Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 327-347.	0.8	0
1706	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110422.	0.2	3
1707	Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 629687.	1.3	15
1708	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 619650.	1.1	17
1709	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. <i>Lung</i> , 2021, 199, 199-211.	1.4	7
1710	Adjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 789-797.	0.8	20
1711	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and \pm -PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	2.9	5

#	ARTICLE	IF	CITATIONS
1712	The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636544.	1.8	10
1713	Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy. <i>Frontiers in Immunology</i> , 2021, 12, 615930.	2.2	12
1714	Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naïve programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study. <i>BMC Cancer</i> , 2021, 21, 108.	1.1	5
1715	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	1.0	7
1716	Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases. <i>Journal of Clinical Medicine</i> , 2021, 10, 634.	1.0	12
1717	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	1.6	20
1718	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 144-150.	0.6	8
1719	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
1720	Inmunoterapia, cáncer y PET. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.0	0
1721	Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. <i>Cancer Discovery</i> , 2021, 11, 1040-1051.	7.7	24
1722	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	0.8	12
1723	Management of Immune Checkpoint Inhibitor—Induced Myocarditis. <i>JACC: CardioOncology</i> , 2021, 3, 157-161.	1.7	22
1724	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	0.7	6
1725	Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 624686.	1.5	13
1726	Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1607.	1.7	19
1727	Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity. <i>PLoS ONE</i> , 2021, 16, e0248260.	1.1	9
1728	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. <i>Cancers</i> , 2021, 13, 1188.	1.7	27
1729	A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. <i>Communications Biology</i> , 2021, 4, 383.	2.0	20

#	ARTICLE	IF	CITATIONS
1730	Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 619209.	2.2	13
1731	Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. <i>Nature Communications</i> , 2021, 12, 1439.	5.8	39
1732	Primary malignant melanoma of uterine cervix treated with pembrolizumab as adjuvant immunotherapy. <i>International Cancer Conference Journal</i> , 2021, 10, 254-258.	0.2	3
1733	A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). <i>Molecular Medicine Reports</i> , 2021, 23, .	1.1	16
1734	Supportive care for new cancer therapies. <i>Current Opinion in Oncology</i> , 2021, 33, 287-294.	1.1	6
1735	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
1736	Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2021, 10, 2618-2626.	1.3	2
1737	Immunotherapy, cancer and PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.1	1
1738	Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. <i>Frontiers in Oncology</i> , 2021, 11, 624780.	1.3	14
1739	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 1446.	1.7	12
1740	Immune Checkpoint Inhibitors in the Treatment of Cancer. <i>Current Clinical Pharmacology</i> , 2022, 17, 103-113.	0.2	18
1741	Nivolumab for the treatment of esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1-7.	1.4	9
1742	Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. <i>Cells</i> , 2021, 10, 927.	1.8	8
1743	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Radiology</i> , 2021, 299, 109-119.	3.6	54
1744	Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review. <i>BMC Medicine</i> , 2021, 19, 88.	2.3	5
1745	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
1746	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	0.5	1
1747	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130

#	ARTICLE	IF	CITATIONS
1748	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	0.8	54
1749	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	2.9	62
1750	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	1.8	34
1751	Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 3693-3705.	0.4	15
1752	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
1753	Modelling treatment-response rates. <i>Nature Biomedical Engineering</i> , 2021, 5, 295-296.	11.6	0
1754	Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2021, 13, 2618-2627.	0.6	12
1755	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17
1756	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
1757	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
1758	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1185-1196.	0.6	8
1759	Narrative review of immunotherapy and radiation therapy in elderly patients. <i>Translational Cancer Research</i> , 2021, 10, 2620-2631.	0.4	1
1760	Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 391-403.	0.6	10
1761	Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy. <i>Journal of the American Chemical Society</i> , 2021, 143, 8391-8401.	6.6	64
1762	Safety and discontinuation rate of immune checkpoint inhibitors used in patients with solid and hematological malignancies. A population based retrospective analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 771-776.	0.5	2
1763	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatoooncology Group. <i>European Journal of Cancer</i> , 2021, 149, 1-10.	1.3	10
1764	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
1765	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4109-4125.	3.2	65

#	ARTICLE	IF	CITATIONS
1766	Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 628243.	1.3	1
1767	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	1
1768	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
1769	Phase I trial of intravesical <i>Bacillus Calmette-Guérin</i> combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous <i>Bacillus Calmette-Guérin</i> treatment. <i>World Journal of Urology</i> , 2021, 39, 3807-3813.	1.2	10
1770	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	1.3	15
1771	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
1772	Development of new therapeutic options for the treatment of uveal melanoma. <i>FEBS Journal</i> , 2021, 288, 6226-6249.	2.2	19
1773	Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication. <i>Immunotherapy</i> , 2021, 13, 745-752.	1.0	2
1774	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
1775	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
1776	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	3.3	15
1777	Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases. <i>JAMA Oncology</i> , 2021, 7, 845.	3.4	56
1778	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
1779	Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. <i>Journal of Immunotherapy</i> , 2021, 44, 362-370.	1.2	14
1780	The role of immunotherapy and molecularly-targeted therapy in the treatment of melanoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14
1781	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
1782	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5
1783	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	0.9	12

#	ARTICLE	IF	CITATIONS
1784	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	3.2	33
1785	Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III-IV Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 693655.	1.3	16
1786	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
1787	Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Cancer Science</i> , 2021, 112, 3005-3017.	1.7	31
1788	A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. <i>Clinical and Translational Oncology</i> , 2021, 23, 2415-2430.	1.2	8
1789	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021, 53, 961-978.	0.9	4
1790	Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment. <i>Case Reports in Gastroenterology</i> , 2021, 15, 645-651.	0.3	2
1791	Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma. <i>Journal of Skin Cancer</i> , 2021, 2021, 1-3.	0.5	2
1792	Primary Adrenal Insufficiency and Acute Cardiomyopathy in a Patient With Colorectal Cancer Treated With Dual Immune Checkpoint Inhibitors. <i>Clinical Colorectal Cancer</i> , 2021, 20, e249-e252.	1.0	3
1793	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
1794	Emerging data on nivolumab for esophageal squamous cell carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 845-854.	1.4	1
1795	Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 640099.	1.6	3
1796	Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	92
1797	Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8017.	1.8	15
1798	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1244-1256.	0.9	4
1799	Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. <i>Melanoma Research</i> , 2021, 31, 464-471.	0.6	2
1800	Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 702287.	1.3	31
1801	Treatment of Advanced Metastatic Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021164S.	0.5	10

#	ARTICLE	IF	CITATIONS
1802	T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model. <i>Journal of Hepatology</i> , 2021, 75, 1083-1095.	1.8	17
1803	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19
1804	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
1805	JAML promotes CD8 and T cell antitumor immunity and is a novel target for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	11
1806	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. <i>JAMA Oncology</i> , 2021, 7, 1573-1574.	3.4	1
1807	Tumor-on-chip modeling of organ-specific cancer and metastasis. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113798.	6.6	57
1808	Radiochemotherapy upregulates expression of checkpoint receptors on circulating T cells. <i>International Journal of Radiation Biology</i> , 2021, 97, 1-6.	1.0	2
1809	Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255716.	1.1	17
1810	Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. <i>Cancers</i> , 2021, 13, 4289.	1.7	30
1811	Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. , 2021, 224, 107829.		12
1812	Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103417.	2.0	18
1813	Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 426.	1.8	7
1814	The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 30.	1.8	32
1815	Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. <i>Pancreatology</i> , 2021, 21, 942-949.	0.5	16
1816	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 705378.	2.2	17
1817	p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 728381.	2.2	5
1818	Long-term Overall Survival and Predictors in Anti-PD-1-naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318.	1.2	4
1819	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52

#	ARTICLE	IF	CITATIONS
1820	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
1821	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. <i>Journal of Cellular Physiology</i> , 2022, 237, 346-372.	2.0	13
1822	Role of Different Peptides for Cancer Immunotherapy. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2777-2793.	0.9	7
1823	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021, 39, 789-796.	0.6	5
1824	Anti-“cytotoxic T-lymphocyte”-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 162-170.	0.9	6
1825	A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 706915.	1.3	8
1826	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
1827	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
1828	Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. , 2021, 9, e003521.		56
1829	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. <i>Vaccines</i> , 2021, 9, 1060.	2.1	39
1830	Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II. <i>Southern Medical Journal</i> , 2021, 114, 614-619.	0.3	2
1831	Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 3-8.	0.5	9
1832	Non-coding RNAs in melanoma: Biological functions and potential clinical applications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 219-231.	2.0	11
1833	TIM-3: An update on immunotherapy. <i>International Immunopharmacology</i> , 2021, 99, 107933.	1.7	71
1834	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	3.5	26
1835	Cancer cell immune mimicry delineates onco-immunologic modulation. <i>IScience</i> , 2021, 24, 103133.	1.9	9
1836	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
1837	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	3.3	48

#	ARTICLE	IF	CITATIONS
1838	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
1839	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
1840	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. Open Journal of Obstetrics and Gynecology, 2021, 11, 146-161.	0.1	2
1841	Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.		2
1842	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. OncoImmunology, 2021, 10, 1863631.	2.1	16
1843	Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry. Clinical Cancer Research, 2021, 27, 1987-1996.	3.2	38
1844	CML End Phase and Blast Crisis: Implications and Management. Hematologic Malignancies, 2021, , 179-196.	0.2	0
1845	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review. Dermatology Practical and Conceptual, 2021, 11, e2021155.	0.5	25
1846	Immune checkpoint inhibitorsâ€”induced eosinophilic pneumonia: A case report. Thoracic Cancer, 2021, 12, 720-724.	0.8	7
1848	Targeting cancer metastasis with antibody therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1698.	3.3	17
1849	Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review. Journal of Cancer, 2021, 12, 1318-1333.	1.2	27
1850	Towards the use of localised delivery strategies to counteract cancer therapyâ€”induced cardiotoxicities. Drug Delivery and Translational Research, 2021, 11, 1924-1942.	3.0	7
1851	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
1852	Immune Therapies. Molecular and Translational Medicine, 2019, , 239-253.	0.4	1
1853	Clinical Applications of Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research, 2020, 215, 147-160.	1.8	8
1854	The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer. Advances in Experimental Medicine and Biology, 2020, 1268, 211-226.	0.8	11
1855	Prognostic Factors and Their Role in the Management of CUP. , 2016, , 45-65.		1
1856	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1

#	ARTICLE	IF	CITATIONS
1858	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
1859	Cancer Immunotherapy Targeting Co-signal Molecules. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 313-326.	0.8	4
1860	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
1861	Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 195-203.	1.8	11
1862	Melanoma cutáneo en el anciano: revisión de un problema creciente. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 434-447.	0.2	28
1864	Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102979.	2.0	5
1865	Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 22-30.	0.4	103
1866	Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. <i>International Immunopharmacology</i> , 2020, 84, 106601.	1.7	35
1867	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1239-1253.	0.6	56
1868	The <i>TERT</i> copy number gain is sensitive to telomerase inhibitors in human melanoma. <i>Clinical Science</i> , 2020, 134, 193-205.	1.8	15
1869	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. <i>Acta Oncológica</i> , 2020, 59, 438-443.	0.8	7
1870	TAM kinase inhibition and immune checkpoint blockade “a winning combination in cancer treatment?”. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 141-151.	1.5	17
1871	Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. <i>Oncolmunology</i> , 2021, 10, 1864909.	2.1	18
1872	Management of checkpoint inhibitor-associated renal toxicities. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 215-223.	0.6	6
1873	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa140.	0.4	6
1874	PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival. <i>Melanoma Research</i> , 2017, 27, 565-572.	0.6	19
1875	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	0.6	15
1876	The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 76-81.	0.6	7

#	ARTICLE	IF	CITATIONS
1877	Pre-examinations Improve Automated Metastases Detection on Cranial MRI. <i>Investigative Radiology</i> , 2021, 56, 320-327.	3.5	5
1879	Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report. <i>Thoracic Cancer</i> , 2020, 11, 3396-3400.	0.8	4
1880	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. <i>Cancer Science</i> , 2020, 111, 1943-1957.	1.7	24
1881	ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 291-308.	1.6	42
1882	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. <i>Journal of Clinical Investigation</i> , 2019, 129, 3324-3338.	3.9	209
1883	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
1884	Metabolic regulation of immune responses: therapeutic opportunities. <i>Journal of Clinical Investigation</i> , 2016, 126, 2031-2039.	3.9	78
1885	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	3.9	64
1886	Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492097636.	0.6	6
1887	Mesothelioma: is chemotherapy alone a thing of the past?. , 2020, , 232-249.		1
1888	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
1889	A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. <i>American Journal of Case Reports</i> , 2019, 20, 106-110.	0.3	7
1890	Immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Clinical Cases</i> , 2019, 7, 405-418.	0.3	171
1891	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
1892	Blockade of programmed cell death protein-1 pathway for the treatment of melanoma. <i>Journal of Antioxidant Activity</i> , 2017, 1, 1-11.	1.0	12
1893	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	12
1894	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 674-683.	1.8	10
1895	A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab. <i>Cardiology Research</i> , 2019, 10, 120-123.	0.5	11

#	ARTICLE	IF	CITATIONS
1896	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
1897	Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis. Open Medicine (Poland), 2020, 15, 447-456.	0.6	8
1898	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocrine Connections, 2020, 9, 318-325.	0.8	23
1899	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.2	60
1900	New-onset insulin-dependent diabetes due to nivolumab. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	14
1901	French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer, 2019, 26, G1-G18.	1.6	95
1902	Cancer and Heart Failure: Understanding the Intersection. Cardiac Failure Review, 2017, 03, 66-70.	1.2	10
1903	Melanoma Immunotherapy: Mechanisms and Opportunities. Investigative Dermatology and Venereology Research, 2016, 2, 1-7.	0.1	1
1904	Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. Advances in Modern Oncology Research, 2016, 2, 18.	0.1	5
1905	Large-scale analysis reveals the specific clinical and immune features of CD155 in glioma. Aging, 2019, 11, 5463-5482.	1.4	20
1906	Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging, 2020, 12, 5479-5499.	1.4	25
1907	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget, 2016, 7, 64300-64308.	0.8	44
1908	Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. Oncotarget, 2016, 7, 80855-80871.	0.8	2
1909	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget, 2016, 7, 81493-81511.	0.8	14
1910	Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. Oncotarget, 2017, 8, 4520-4529.	0.8	9
1911	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget, 2017, 8, 59901-59914.	0.8	64
1912	<i>Cblb</i>-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget, 2017, 8, 41841-41853.	0.8	19
1913	Tumor reductive therapies and antitumor immunity. Oncotarget, 2017, 8, 55736-55749.	0.8	11

#	ARTICLE	IF	CITATIONS
1914	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , 2017, 8, 76029-76043.	0.8	7
1915	<i>Solanum incanum</i> extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis. <i>Oncotarget</i> , 2017, 8, 103509-103517.	0.8	30
1916	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	0.8	76
1917	Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 114268-114280.	0.8	169
1918	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2
1919	Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer. <i>Oncotarget</i> , 2018, 9, 23482-23493.	0.8	17
1920	Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. <i>Oncotarget</i> , 2018, 9, 28903-28909.	0.8	37
1921	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 32298-32304.	0.8	53
1922	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
1923	Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	0.8	118
1924	Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. <i>Oncotarget</i> , 2015, 6, 43127-43134.	0.8	19
1925	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. <i>Oncotarget</i> , 0, 7, 42698-42715.	0.8	34
1926	Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269.	0.7	19
1927	Acquired resistance mechanisms to immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 547-547.	0.7	2
1928	Neopterin as a biomarker of immune response in cancer patients. <i>Annals of Translational Medicine</i> , 2017, 5, 280-280.	0.7	42
1929	Immune checkpoint pathways in non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 88-88.	0.7	13
1930	Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. <i>Chinese Clinical Oncology</i> , 2017, 6, 31-31.	0.4	12
1931	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7

#	ARTICLE	IF	CITATIONS
1932	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era. <i>Current Medicinal Chemistry</i> , 2019, 26, 1002-1018.	1.2	11
1933	Immune Checkpoint Inhibitors in AML-A New Frontier. <i>Current Cancer Drug Targets</i> , 2020, 20, 545-557.	0.8	5
1934	Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 290-303.	0.9	14
1935	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1415-1430.	0.9	3
1936	Immune Blockade Inhibition in Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 5607-5622.	0.5	37
1937	Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. <i>Anticancer Research</i> , 2018, 38, 107-112.	0.5	31
1938	MÃ©lanome : effets indÃ©sirables des traitements innovants. <i>Oncologie</i> , 2018, 20, 11-17.	0.2	2
1939	Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. <i>Journal of Korean Medical Science</i> , 2019, 34, e186.	1.1	8
1940	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 576027.	1.5	20
1942	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
1943	TIME Is a Great Healerâ€™ Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes. <i>Cells</i> , 2021, 10, 11.	1.8	13
1944	Immunotherapy in human colorectal cancer: Challenges and prospective. <i>World Journal of Gastroenterology</i> , 2016, 22, 6362.	1.4	41
1945	Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. <i>World Journal of Gastroenterology</i> , 2020, 26, 353-365.	1.4	54
1946	Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 590-594.	0.4	8
1947	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27
1948	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015, 3, 265.	0.7	19
1949	Immune checkpoint inhibitors: therapeutic advances in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 267.	0.7	47
1950	Immune based therapy for melanoma. <i>Indian Journal of Medical Research</i> , 2016, 143, 135.	0.4	19

#	ARTICLE	IF	CITATIONS
1951	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 68-77.	0.6	8
1952	Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 78-81.	0.6	8
1953	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. <i>Cancer Research and Treatment</i> , 2020, 52, 730-738.	1.3	7
1954	Seroconversion of Hbsag in Melanoma Patient with Hepatitis B Treated with Checkpoint Inhibitors: A Case Report. <i>Journal of Clinical Case Reports</i> , 2017, 07, .	0.0	2
1955	Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients. <i>Journal of Biosciences and Medicines</i> , 2019, 07, 1-12.	0.1	1
1956	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 270-280.	0.8	8
1957	Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 58-72.	0.2	7
1958	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
1959	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 329-354.	2.3	383
1960	Evaluating cost benefits of combination therapies for advanced melanoma. <i>Drugs in Context</i> , 2016, 5, 1-14.	1.0	19
1961	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2017, 9, e1774.	0.2	17
1962	Evaluating Optimal Treatment for Melanoma: A Network Meta-Analysis. <i>Chinese Journal of Plastic and Reconstructive Surgery</i> , 2021, 3, 27-31.	0.1	0
1963	CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 97-102.	1.8	12
1964	NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 754541.	1.3	16
1965	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
1966	Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. <i>Cancers</i> , 2021, 13, 5061.	1.7	9
1967	Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651553.	1.3	3
1968	Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 734872.	1.3	9

#	ARTICLE	IF	CITATIONS
1969	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12
1970	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
1971	Hematologic complications of immune checkpoint inhibitors. <i>Blood</i> , 2022, 139, 3594-3604.	0.6	30
1972	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. <i>Molecular Imaging and Biology</i> , 2022, 24, 425-433.	1.3	3
1973	A case of simultaneous malignant melanoma and squamous cell carcinoma of the oral cavity. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2015, 61, 580-584.	0.0	0
1974	Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease. <i>Journal of Blood & Lymph</i> , 2015, 05, .	0.0	0
1975	çš®è†šè...«ç~â...ç—«ã®ãf^ãf”ãffã,ã,1. <i>Skin Cancer</i> , 2015, 30, 58-61.	0.1	0
1976	âĒ»âĴãf»è—âĴç”ç©ŕã«ãšãã,ç—ã¼æ°è”è”. <i>Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology</i> , 2016, 30, 190-197.	0.0	0
1977	Targeted Cancer Therapy. <i>Nishinohon Journal of Dermatology</i> , 2016, 78, 221-228.	0.0	0
1978	Cancer Vaccines in Castration Resistant Prostate Cancerâ€”An Evolution in Design. , 2016, , 107-124.		0
1979	Nivolumab in Metastatic Nonâ€”Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	0
1980	Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.. <i>University of Ottawa Journal of Medicine</i> , 2016, 6, 49-52.	0.0	0
1981	Advances in lung cancer with a focus on ATS 2016 updates. <i>Journal of Thoracic Disease</i> , 2016, 8, S566-S568.	0.6	0
1984	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. <i>Pediatric Oncology</i> , 2017, , 231-267.	0.5	0
1985	Cancer Drug Delivery. , 2017, , 185-228.		0
1986	Principles of Cancer Targeted Therapy in Older Adults. , 2017, , 1-15.		0
1987	Combinational Immunotherapy of Gastric Cancer. , 2017, , 163-175.		0
1988	Experience using nivolumab for the treatment of malignant melanoma of mandibular gingiva. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2017, 63, 558-563.	0.0	0

#	ARTICLE	IF	CITATIONS
1989	Immunotherapy for Gynecologic Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 69-85.	0.0	0
1990	The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506.		0
1991	Re-Thinking the Interplay between Tumorigenesis and Immunity. <i>Journal of Cell Signaling</i> , 2017, 01, .	0.3	0
1993	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
1994	Familial Syndromes. , 2018, , 1-55.		0
1995	MÃ©lanome : actualitÃ©s physiopathologiques et stratÃ©gie thÃ©rapeutique. <i>Oncologie</i> , 2018, 20, 3-10.	0.2	1
1996	Familial Syndromes. , 2018, , 1-54.		0
1997	Immune Checkpoint Inhibition. , 2018, , 315-353.		0
1998	Voluntary Wheel Running Regulates Tumor Immunogenicity and Response to Immune Checkpoint Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1999	PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkinâ€™s Lymphoma. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2018, 11, 213-219.	0.1	3
2000	Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	1
2001	ToxicitÃ©s sÃ©vÃ©res des immunothÃ©rapies du cancer. <i>Medecine Intensive Reanimation</i> , 2018, 27, 522-536.	0.1	0
2002	Genomic Applications in Melanoma. , 2019, , 509-540.		0
2003	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
2004	The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2019, 8, 379.	0.0	0
2005	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
2006	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
2007	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0

#	ARTICLE	IF	CITATIONS
2008	Targeted and Immune Therapy for Periocular and Orbital Malignancies. Current Practices in Ophthalmology, 2019, , 83-97.	0.1	0
2010	Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 155-179.	0.1	0
2011	A case of sudden renal dysfunction caused by pembrolizumab for malignant melanoma on the left heel and successfully treated with steroid. Skin Cancer, 2019, 33, 201-205.	0.1	0
2012	Precision oncology: myth or reality?. Bulletin of Russian State Medical University, 2019, , 5-14.	0.3	0
2013	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. Journal of the Advanced Practitioner in Oncology, 2019, 10, 367-386.	0.2	0
2014	Combined Immunotherapy in Metastatic Melanoma with Unknown Primary. Cureus, 2019, 11, e5324.	0.2	1
2016	Budosenid Treatment of Avelumab Induced Autoimmune Colitis in Patient With Metastatic Merkel Cell Carcinoma; A Case Report. Clinical Oncology and Research, 2019, , 1-4.	0.1	0
2017	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
2018	Nivolumab in real-life clinical practice. IssledovaniĀ I Praktika V Medicine, 2019, 6, 84-91.	0.1	2
2020	Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82.		0
2021	Familial Syndromes. , 2020, , 1793-1834.		0
2022	Systemic Therapy of Advanced Liver Cancer. , 2020, , 661-666.		0
2023	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
2026	Natural killer cells and immunotherapy based on monoclonal antibodies. Biomedical Reviews, 2021, 31, 61.	0.6	0
2028	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
2029	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
2030	Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. , 2021, 25, 1-1.		4
2031	Hepatobiliary Adverse Events. Advances in Experimental Medicine and Biology, 2020, 1244, 271-276.	0.8	3

#	ARTICLE	IF	CITATIONS
2032	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 21, 162-186.	0.9	2
2033	Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers. <i>Epigenomics</i> , 2020, 12, 2155-2171.	1.0	4
2034	CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC. <i>Precision Cancer Medicine</i> , 0, 3, 34-34.	1.8	0
2035	Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2021, 55, 232-241.	0.4	3
2037	Recalibrating Immunity in Cancer and Autoimmune Inflammation by Galectin-1-Driven Regulatory Circuits. <i>Science Reviews - From the End of the World</i> , 2020, 2, 42-63.	0.2	0
2039	Immunotherapy agents combination in metastatic melanoma " case presentation. <i>Oncolog-Hematolog Ro</i> , 2020, 1, 28.	0.0	0
2040	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
2041	Principles of Cancer Targeted Therapy in Older Adults. , 2020, , 881-894.		0
2042	Future Therapies for Malignant Brainstem Tumors. , 2020, , 347-392.		0
2043	Tumor Microenvironment in Penile Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 291-307.	0.8	0
2044	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
2045	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
2047	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. <i>Cancers</i> , 2021, 13, 5550.	1.7	4
2048	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021, 9, 79.	2.8	36
2049	Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 5811-5816.	0.5	4
2050	Cancer Drug Delivery. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 52-95.	0.3	0
2051	Immunotherapy for Pediatric Sarcomas. <i>Pediatric Oncology</i> , 2021, , 165-180.	0.5	0
2053	Targeted drug combinations: avant-garde oncology. <i>Annals of Translational Medicine</i> , 2015, 3, 159.	0.7	0

#	ARTICLE	IF	CITATIONS
2054	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 389-95.	0.2	3
2055	Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 313.	0.7	3
2056	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. <i>Cancer Biology and Medicine</i> , 2015, 12, 316-27.	1.4	5
2057	HemOnc Today Melanoma and Cutaneous Malignancies and American College of Cardiology. <i>P and T</i> , 2016, 41, 326-30.	1.0	0
2058	Immune evasion pathways and the design of dendritic cell-based cancer vaccines. <i>Discovery Medicine</i> , 2016, 21, 135-42.	0.5	2
2059	Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 277-285.	1.0	9
2060	Nivolumab in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 220-225.	0.2	0
2062	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	8
2065	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. <i>American Journal of Cancer Research</i> , 2018, 8, 1947-1956.	1.4	6
2066	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.6	18
2068	Diagnosis and Management of Immune Checkpoint Inhibitor Colitis. <i>Gastroenterology and Hepatology</i> , 2021, 17, 358-366.	0.2	3
2069	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	1
2070	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 874-876.	0.4	3
2071	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
2072	Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 765644.	2.2	5
2073	Regulation of Adaptive Tumor Immunity by Non-Coding RNAs. <i>Cancers</i> , 2021, 13, 5651.	1.7	5
2074	Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 209, 114515.	1.4	5
2075	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
2076	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	0.8	6
2077	Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. <i>European Journal of Radiology</i> , 2022, 146, 110107.	1.2	8
2078	TGFÎ²2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 763877.	2.2	5
2079	Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. <i>Oncologist</i> , 2022, 27, e126-e132.	1.9	8
2080	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
2081	Endocrine Complications of Biological Cancer Therapies. , 2022, , 1775-1778.		0
2082	Immunotherapy of cancer in the era of checkpoint inhibitor. <i>Clinical and Experimental Metastasis</i> , 2021, 39, 231.	1.7	1
2083	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
2084	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
2085	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121527.	2.6	16
2086	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	6.9	17
2087	A Need for More Molecular Profiling in Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 785064.	1.3	1
2088	Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000889.	0.8	10
2090	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	8
2091	Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	6
2092	New Therapeutic Approaches for Conjunctival Melanoma – What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
2093	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
2094	Vectorized Treg-depleting Î±CTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject – coldâ€™ tumors. , 2022, 10, e003488.		14

#	ARTICLE	IF	CITATIONS
2095	Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma. <i>Future Oncology</i> , 2022, 18, 1343-1355.	1.1	2
2096	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
2097	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
2098	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. <i>International Immunopharmacology</i> , 2022, 106, 108617.	1.7	5
2099	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	0.8	26
2100	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
2101	New Checkpoint Inhibitors and Immunotherapies for Solid Tumours. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 90.	0.1	0
2102	The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1679.	0.3	5
2103	Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma. , 2022, , 339-384.		0
2104	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
2105	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	2.2	1
2106	Effective Combination Immunotherapy through Vessel Normalization Using a Cancer-Targeting Antiangiogenic Peptide-Antibody Hybrid. <i>Advanced Therapeutics</i> , 0, , 2100151.	1.6	0
2107	Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 331-338.	3.3	16
2108	Sex dimorphism in the tumor microenvironment – From bench to bedside and back. <i>Seminars in Cancer Biology</i> , 2022, 86, 166-179.	4.3	8
2109	The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies. <i>Frontiers in Immunology</i> , 2022, 13, 837645.	2.2	16
2110	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
2111	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
2112	The Predictive Individual Effect for Survival Data. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 492-500.	0.8	1

#	ARTICLE	IF	CITATIONS
2113	Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. <i>Biomedicines</i> , 2022, 10, 673.	1.4	4
2114	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	2.8	16
2115	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. <i>Life</i> , 2022, 12, 360.	1.1	1
2116	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
2117	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25
2118	Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590.	1.7	2
2119	Assessing the Future of Solid Tumor Immunotherapy. <i>Biomedicines</i> , 2022, 10, 655.	1.4	34
2120	Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. <i>Frontiers in Immunology</i> , 2022, 13, 844401.	2.2	15
2121	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	42
2122	Melanoma: An update on systemic therapies. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 515-524.	0.6	26
2123	Delayed-Onset Inflammatory Optic Nerve Sheath Mass and Perineuritis Following Cessation of Ipilimumab and Nivolumab Therapy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 0, Publish Ahead of Print, .	0.4	1
2124	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
2125	Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy. <i>Cancers</i> , 2022, 14, 1823.	1.7	4
2126	Nanotechnology-based multifunctional vaccines for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 437, 135505.	6.6	13
2127	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2022, 42, 101748.	0.8	2
2128	Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. <i>Acta Oncologica</i> , 2022, 61, 533-544.	0.8	10
2129	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
2130	Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. <i>Frontiers in Oncology</i> , 2022, 12, 880876.	1.3	21

#	ARTICLE	IF	CITATIONS
2132	Immunotherapy of Neuroblastoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2022, 28, 3196-3206.	3.2	29
2197	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	0.4	7
2200	Current therapeutics and treatment options in TNBC. , 2022, , 61-94.		4
2201	Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice. <i>Cancers</i> , 2022, 14, 2214.	1.7	5
2202	Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection. <i>JGH Open</i> , 2022, 6, 309-316.	0.7	6
2203	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	42
2204	The Use and Technique of Sentinel Node Biopsy for Skin Cancer. <i>Plastic and Reconstructive Surgery</i> , 2022, 149, 995e-1008e.	0.7	0
2205	Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation. <i>Journal of Biological Chemistry</i> , 2022, 298, 102013.	1.6	2
2206	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
2207	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6
2208	Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. <i>IScience</i> , 2022, 25, 104353.	1.9	3
2209	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
2210	Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 236-248.	2.0	9
2211	Temporal bone mucosal melanoma masquerading as otomastoiditis. <i>Otolaryngology Case Reports</i> , 2022, 24, 100438.	0.0	0
2212	The roles of TGF- β 2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors. , 2022, 240, 108211.		21
2214	Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2021, 47, 239-249.	0.0	0
2215	A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient/microsatellite instability-high metastatic colon cancer: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	4
2216	T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. <i>Thyroid</i> , 2022, 32, 789-798.	2.4	3

#	ARTICLE	IF	CITATIONS
2217	Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study. <i>BMJ, The</i> , 2022, 377, e069155.	3.0	16
2218	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 2638.	1.7	12
2219	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
2220	Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1003-1010.	0.5	2
2221	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
2222	Diabetes and cancer: Optimising glycaemic control. <i>Journal of Human Nutrition and Dietetics</i> , 2023, 36, 504-513.	1.3	3
2224	Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2225	An in-library ligation strategy and its application in CRISPR/Cas9 screening of high-order gRNA combinations. <i>Nucleic Acids Research</i> , 2022, 50, 6575-6586.	6.5	1
2226	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
2227	ZFP64 transcriptionally activates PD-1 and CTLA-4 and plays an oncogenic role in esophageal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2022, 622, 72-78.	1.0	1
2228	Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma. <i>European Journal of Cancer</i> , 2022, 171, 10-12.	1.3	3
2229	Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2230	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. <i>Nature Cancer</i> , 2022, 3, 665-680.	5.7	18
2231	Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	134
2232	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
2233	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
2234	Research progress of <sc>PD&€1</sc> non&€glycosylation in cancer immunotherapy. <i>Scandinavian Journal of Immunology</i> , 2022, 96, .	1.3	2
2236	Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	3

#	ARTICLE	IF	CITATIONS
2237	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	8
2238	Pulmonary adverse events following immune checkpoint inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 391-398.	1.2	9
2239	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2240	Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	7
2241	PDL1Binder: Identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
2242	Two cases of ulcerative colitis that developed while using abatacept. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
2243	Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, .	5.6	18
2244	Adoptive Cell Therapy for Advanced Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 255-256.	1.0	0
2245	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists's Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
2246	Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. <i>British Journal of Dermatology</i> , 2022, 187, 962-969.	1.4	15
2247	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials. <i>JAMA Oncology</i> , 2022, 8, 1294.	3.4	12
2248	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	44
2249	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. <i>Current Medicinal Chemistry</i> , 2023, 30, 3215-3237.	1.2	3
2250	Cutaneous melanoma: An update on pathogenesis, prevention, and treatment. <i>Dermatological Reviews</i> , 2022, 3, 384-399.	0.3	0
2251	Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
2252	Glucose's Thymidine Ratio as a Metabolism Index Using 18F-FDG and 18F-FLT PET Uptake as a Potential Imaging Biomarker for Evaluating Immune Checkpoint Inhibitor Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9273.	1.8	1
2253	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
2254	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1

#	ARTICLE	IF	CITATIONS
2255	Image-guided in situ cancer vaccination with combination of multi-functional nano-adjuvant and an irreversible electroporation technique. <i>Biomaterials</i> , 2022, 289, 121762.	5.7	11
2256	The immune-related role of beta-2-microglobulin in melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
2257	Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 174, 176-184.	1.3	7
2258	Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166516.	1.8	0
2259	Vulvovaginal melanoma. , 2023, , 279-304.		0
2260	Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Targeted Oncology</i> , 2022, 17, 583-589.	1.7	0
2261	Primary lacrimal sac melanoma: a case report describing the novel use of fine needle aspiration cytology (FNAC) for diagnosis, together with literature review and immunotherapy treatment update. <i>Orbit</i> , 2024, 43, 270-279.	0.5	0
2262	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 110, 102463.	3.4	10
2263	Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. <i>Theranostics</i> , 2022, 12, 6106-6129.	4.6	14
2264	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
2265	Rheumatology (Arthritis and Myositis). , 2022, , 301-313.		0
2266	Cardiology (Heart). , 2022, , 7-27.		0
2267	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
2268	Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. <i>Biomedicines</i> , 2022, 10, 2146.	1.4	0
2269	Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29390.	0.4	0
2270	Immune checkpoint inhibitors and their impact on liver enzymes and attenuation. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
2271	Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>European Journal of Endocrinology</i> , 2022, 187, G1-G21.	1.9	35
2272	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9

#	ARTICLE	IF	CITATIONS
2273	Case Report of a Malignant Melanoma Patient with Longitudinally Extensive Transverse Myelitis: Immune-Related Adverse Event or Human Herpesvirus-7 Infection?. SN Comprehensive Clinical Medicine, 2022, 4, .	0.3	1
2274	Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma. Cancer Research, 2022, 82, 3198-3200.	0.4	0
2275	Clinical predictors of survival in real world practice in stage IV melanoma. Cancer Reports, 0, , .	0.6	1
2276	Neoantigens and their clinical applications in human gastrointestinal cancers. World Journal of Surgical Oncology, 2022, 20, .	0.8	1
2277	Molecular Biomarkers of Response to Cancer Immunotherapy. Clinics in Laboratory Medicine, 2022, 42, 469-484.	0.7	3
2278	Emerging Trends in Immunotherapy for Cancer. Diseases (Basel, Switzerland), 2022, 10, 60.	1.0	17
2279	Intratumoral administration of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. , 2022, 10, e005141.		11
2280	Tumor immune microenvironment and systemic response in breast cancer. , 2022, 39, .		6
2282	Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. Frontiers in Immunology, 0, 13, .	2.2	11
2283	A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clinical Cancer Research, 2022, 28, 5088-5097.	3.2	12
2284	From simplicity to complexity in current melanoma models. Experimental Dermatology, 2022, 31, 1818-1836.	1.4	3
2285	Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience. Biomedicines, 2022, 10, 2528.	1.4	2
2286	Targeted Therapy and Immunotherapy in Melanoma. Dermatologic Clinics, 2023, 41, 65-77.	1.0	14
2287	Is There a Role for Exercise When Treating Patients with Cancer with Immune Checkpoint Inhibitors? A Scoping Review. Cancers, 2022, 14, 5039.	1.7	4
2288	Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlentherapie Und Onkologie, 2023, 199, 121-130.	1.0	7
2290	Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma. JAMA Dermatology, 2022, 158, 1387.	2.0	2
2291	Update on immune checkpoint therapy for melanoma. Dermatological Reviews, 0, , .	0.3	0
2292	Clinical cancer immunotherapy: Current progress and prospects. Frontiers in Immunology, 0, 13, .	2.2	39

#	ARTICLE	IF	CITATIONS
2293	PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30561.	0.4	4
2294	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
2296	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
2297	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2298	Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. <i>Protein Expression and Purification</i> , 2023, 202, 106196.	0.6	2
2299	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. <i>OncImmunology</i> , 2022, 11, .	2.1	3
2300	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. <i>Cancer Cell</i> , 2022, 40, 1324-1340.e8.	7.7	11
2301	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	1.1	4
2302	The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188826.	3.3	5
2303	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <i>International Immunopharmacology</i> , 2022, 113, 109300.	1.7	4
2304	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
2305	Pulmonary effects of cancer treatments. , 2022, , 253-264.		0
2306	Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups. <i>Cancers</i> , 2022, 14, 5938.	1.7	4
2307	Imaging of Activated T Cells. <i>Journal of Nuclear Medicine</i> , 2023, 64, 30-33.	2.8	1
2309	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
2310	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
2311	Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5645-5653.	1.2	3
2312	Macrophage GSK3 β -deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. , 2022, 10, e005655.		10

#	ARTICLE	IF	CITATIONS
2313	Estimated Costs of the Ipilimumab+Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. <i>Cancers</i> , 2023, 15, 31.	1.7	1
2314	Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. <i>Journal of Dermatology</i> , 2023, 50, 525-535.	0.6	3
2315	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. <i>Cell Reports Medicine</i> , 2023, 4, 100868.	3.3	16
2316	Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 0, , .	1.7	1
2318	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 343-356.	1.2	2
2320	Phytochemical Constituents and Derivatives of <i>Cannabis sativa</i> ; Bridging the Gap in Melanoma Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 859.	1.8	8
2321	Severe colitis in patients with melanoma treated with <scp>BRAF</scp>/<scp>MEK</scp> inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 792-799.	1.9	3
2322	Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial). <i>Journal of Thoracic Disease</i> , 2023, .	0.6	1
2323	ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
2324	Tumor immunology. , 2023, , 245-452.		0
2325	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients's Survival: Single Center Experience and Literature Review. <i>Cancers</i> , 2023, 15, 888.	1.7	5
2326	ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. <i>Cancers</i> , 2023, 15, 878.	1.7	6
2327	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. <i>Cancers</i> , 2023, 15, 852.	1.7	6
2328	Imaging the immune cell in immunotherapy. , 2023, , 197-238.		1
2329	Liquid biopsy and immunotherapy: is all that glitter gold?. , 2023, , 83-117.		0
2330	Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. <i>Clinical Therapeutics</i> , 2023, 45, 151-159.	1.1	3
2331	Immunotherapy: Targeting Cancer Cells. <i>Biological and Medical Physics Series</i> , 2023, , 179-217.	0.3	0
2332	Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. <i>Cancers</i> , 2023, 15, 1433.	1.7	3

#	ARTICLE	IF	CITATIONS
2333	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
2335	Ipilimumab-related uveitis and refractory hypotony with a flat chamber in a trabeculectomized eye with exfoliation glaucoma: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2023, 29, 101807.	0.4	2
2336	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
2338	Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2339	The role of potential probiotic strains <i>Lactobacillus reuteri</i> in various intestinal diseases: New roles for an old player. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	11
2340	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
2341	IgG4 expression and IgG4/IgG ratio in the tumour invasion front predict long-term outcomes for patients with intrahepatic cholangiocarcinoma. <i>Pathology</i> , 2023, 55, 508-513.	0.3	2
2342	COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. , 2023, 11, e006246.		10
2343	Immunotherapy in Melanoma: Recent Advances and Future Directions. <i>Cancers</i> , 2023, 15, 1106.	1.7	39
2344	Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. <i>JGH Open</i> , 2023, 7, 87-97.	0.7	4
2345	VISTA expression and patient selection for immune-based anticancer therapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
2346	3D Spheroid Configurations Are Possible Indicators for Evaluating the Pathophysiology of Melanoma Cell Lines. <i>Cells</i> , 2023, 12, 759.	1.8	8
2347	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
2348	Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the <i>RAF1</i> gene. <i>Melanoma Research</i> , 2023, 33, 247-251.	0.6	3
2349	The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. <i>Melanoma Research</i> , 2023, 33, 199-207.	0.6	0
2350	The Renewal of Cancer Immunotherapy. <i>Vaccines</i> , 2023, 11, 592.	2.1	0
2351	Emerging Trends in Immunotherapy for Adult Sarcomas. <i>Oncologist</i> , 0, , .	1.9	2
2352	Editorial: severe colitis induced by targeted therapies in dermatology beyond checkpoint inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 808-809.	1.9	0

#	ARTICLE	IF	CITATIONS
2353	Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4926.	1.2	0
2354	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. , 2023, 11, e005921.		6
2355	Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. <i>Advances in Clinical Medicine</i> , 2023, 13, 3702-3708.	0.0	0
2356	Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy. <i>BMC Urology</i> , 2023, 23, .	0.6	3
2357	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. <i>Cancers</i> , 2023, 15, 1989.	1.7	2
2358	Molecular imaging for cancer immunotherapy. , 2023, 1, 3-17.		4
2359	Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1. <i>Biomolecules</i> , 2023, 13, 636.	1.8	1
2360	Spending, Utilization, and Price Trends for Immune Checkpoint Inhibitors in US Medicaid Programs: An Empirical Analysis from 2011 to 2021. <i>Clinical Drug Investigation</i> , 2023, 43, 289-298.	1.1	5
2361	Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. <i>Molecular and Cellular Biochemistry</i> , 2024, 479, 127-170.	1.4	1
2362	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. <i>Human Genomics</i> , 2023, 17, .	1.4	1
2364	Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma. <i>JAMA Network Open</i> , 2023, 6, e236356.	2.8	3
2365	A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011â€“2021. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
2366	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103988.	2.0	2
2367	Operative management of immune checkpoint colitis following in-transit melanoma: Case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
2368	Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapyâ€“ a narrative review. <i>Future Cardiology</i> , 2023, 19, 91-103.	0.5	6
2382	Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
2389	Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity. <i>International Review of Cell and Molecular Biology</i> , 2023, , 43-86.	1.6	1
2400	Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2023, , 127-143.	0.4	0

#	ARTICLE	IF	CITATIONS
2402	Genetics of Cancer: Past, Present and Future. , 2023, , 1-12.		0
2422	Biomarkers of Prediction of Immunotherapy and Updates on CTLA-4 Therapy. , 2023, , 1-35.		0
2423	Potential of Biotechnology in Cancer Management. , 2023, , 9-44.		0
2429	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0
2432	New Frontiers in Transarterial Chemoembolization: Combination with Systemic Therapies. , 2023, , 107-117.		0
2438	Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. Drug Safety, 2023, 46, 1313-1322.	1.4	1
2454	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
2462	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discover Oncology, 2024, 15, .	0.8	1
2470	Drug-induced liver injury: toxins and antidotes. , 2024, , 195-220.		0
2471	Multifunctional nanocarrier-mediated approaches and conventional therapies for effective treatment of cancer. , 2024, , 35-61.		0
2481	Unleashing the power of antibodies: Engineering for tomorrow's therapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0